Serveur d'exploration Stress et Covid

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Therapeutic spectrum of interferon‐β in ischemic stroke

Identifieur interne : 000952 ( Pmc/Corpus ); précédent : 000951; suivant : 000953

Therapeutic spectrum of interferon‐β in ischemic stroke

Auteurs : Madhuri Wanve ; Harpreet Kaur ; Deepaneeta Sarmah ; Jackson Saraf ; Kanta Pravalika ; Kanchan Vats ; Kiran Kalia ; Anupom Borah ; Dileep R. Yavagal ; Kunjan R. Dave ; Pallab Bhattacharya

Source :

RBID : PMC:7167007

Abstract

Abstract

Ischemic stroke is devastating and a major cause of morbidity and mortality worldwide. To date, only clot retrieval devices and/or intravenous tissue plasminogen activators (tPA) have been approved by the US‐FDA for the treatment of acute ischemic stroke. Therefore, there is an urgent need to develop an effective treatment for stroke that can have limited shortcomings and broad spectrum of applications. Interferon‐beta (IFN‐β), an endogenous cytokine and a key anti‐inflammatory agent, contributes toward obviating deleterious stroke outcomes. Therefore, exploring the role of IFN‐β may be a promising alternative approach for stroke intervention in the future. In the present review, we have discussed about IFN‐β along with its different mechanistic roles in ischemic stroke. Furthermore, therapeutic approaches targeting the inflammatory cascade with IFN‐β therapy that may be helpful in improving stroke outcome are also discussed.


Url:
DOI: 10.1002/jnr.24333
PubMed: 30320448
PubMed Central: 7167007

Links to Exploration step

PMC:7167007

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Therapeutic spectrum of interferon‐β in ischemic stroke</title>
<author>
<name sortKey="Wanve, Madhuri" sort="Wanve, Madhuri" uniqKey="Wanve M" first="Madhuri" last="Wanve">Madhuri Wanve</name>
<affiliation>
<nlm:aff id="jnr24333-aff-0001"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Kaur, Harpreet" sort="Kaur, Harpreet" uniqKey="Kaur H" first="Harpreet" last="Kaur">Harpreet Kaur</name>
<affiliation>
<nlm:aff id="jnr24333-aff-0001"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Sarmah, Deepaneeta" sort="Sarmah, Deepaneeta" uniqKey="Sarmah D" first="Deepaneeta" last="Sarmah">Deepaneeta Sarmah</name>
<affiliation>
<nlm:aff id="jnr24333-aff-0001"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Saraf, Jackson" sort="Saraf, Jackson" uniqKey="Saraf J" first="Jackson" last="Saraf">Jackson Saraf</name>
<affiliation>
<nlm:aff id="jnr24333-aff-0001"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Pravalika, Kanta" sort="Pravalika, Kanta" uniqKey="Pravalika K" first="Kanta" last="Pravalika">Kanta Pravalika</name>
<affiliation>
<nlm:aff id="jnr24333-aff-0001"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Vats, Kanchan" sort="Vats, Kanchan" uniqKey="Vats K" first="Kanchan" last="Vats">Kanchan Vats</name>
<affiliation>
<nlm:aff id="jnr24333-aff-0001"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Kalia, Kiran" sort="Kalia, Kiran" uniqKey="Kalia K" first="Kiran" last="Kalia">Kiran Kalia</name>
<affiliation>
<nlm:aff id="jnr24333-aff-0001"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Borah, Anupom" sort="Borah, Anupom" uniqKey="Borah A" first="Anupom" last="Borah">Anupom Borah</name>
<affiliation>
<nlm:aff id="jnr24333-aff-0002"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Yavagal, Dileep R" sort="Yavagal, Dileep R" uniqKey="Yavagal D" first="Dileep R." last="Yavagal">Dileep R. Yavagal</name>
<affiliation>
<nlm:aff id="jnr24333-aff-0003"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Dave, Kunjan R" sort="Dave, Kunjan R" uniqKey="Dave K" first="Kunjan R." last="Dave">Kunjan R. Dave</name>
<affiliation>
<nlm:aff id="jnr24333-aff-0003"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Bhattacharya, Pallab" sort="Bhattacharya, Pallab" uniqKey="Bhattacharya P" first="Pallab" last="Bhattacharya">Pallab Bhattacharya</name>
<affiliation>
<nlm:aff id="jnr24333-aff-0001"></nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PMC</idno>
<idno type="pmid">30320448</idno>
<idno type="pmc">7167007</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167007</idno>
<idno type="RBID">PMC:7167007</idno>
<idno type="doi">10.1002/jnr.24333</idno>
<date when="2018">2018</date>
<idno type="wicri:Area/Pmc/Corpus">000952</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000952</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a" type="main">Therapeutic spectrum of interferon‐β in ischemic stroke</title>
<author>
<name sortKey="Wanve, Madhuri" sort="Wanve, Madhuri" uniqKey="Wanve M" first="Madhuri" last="Wanve">Madhuri Wanve</name>
<affiliation>
<nlm:aff id="jnr24333-aff-0001"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Kaur, Harpreet" sort="Kaur, Harpreet" uniqKey="Kaur H" first="Harpreet" last="Kaur">Harpreet Kaur</name>
<affiliation>
<nlm:aff id="jnr24333-aff-0001"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Sarmah, Deepaneeta" sort="Sarmah, Deepaneeta" uniqKey="Sarmah D" first="Deepaneeta" last="Sarmah">Deepaneeta Sarmah</name>
<affiliation>
<nlm:aff id="jnr24333-aff-0001"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Saraf, Jackson" sort="Saraf, Jackson" uniqKey="Saraf J" first="Jackson" last="Saraf">Jackson Saraf</name>
<affiliation>
<nlm:aff id="jnr24333-aff-0001"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Pravalika, Kanta" sort="Pravalika, Kanta" uniqKey="Pravalika K" first="Kanta" last="Pravalika">Kanta Pravalika</name>
<affiliation>
<nlm:aff id="jnr24333-aff-0001"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Vats, Kanchan" sort="Vats, Kanchan" uniqKey="Vats K" first="Kanchan" last="Vats">Kanchan Vats</name>
<affiliation>
<nlm:aff id="jnr24333-aff-0001"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Kalia, Kiran" sort="Kalia, Kiran" uniqKey="Kalia K" first="Kiran" last="Kalia">Kiran Kalia</name>
<affiliation>
<nlm:aff id="jnr24333-aff-0001"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Borah, Anupom" sort="Borah, Anupom" uniqKey="Borah A" first="Anupom" last="Borah">Anupom Borah</name>
<affiliation>
<nlm:aff id="jnr24333-aff-0002"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Yavagal, Dileep R" sort="Yavagal, Dileep R" uniqKey="Yavagal D" first="Dileep R." last="Yavagal">Dileep R. Yavagal</name>
<affiliation>
<nlm:aff id="jnr24333-aff-0003"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Dave, Kunjan R" sort="Dave, Kunjan R" uniqKey="Dave K" first="Kunjan R." last="Dave">Kunjan R. Dave</name>
<affiliation>
<nlm:aff id="jnr24333-aff-0003"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Bhattacharya, Pallab" sort="Bhattacharya, Pallab" uniqKey="Bhattacharya P" first="Pallab" last="Bhattacharya">Pallab Bhattacharya</name>
<affiliation>
<nlm:aff id="jnr24333-aff-0001"></nlm:aff>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Journal of Neuroscience Research</title>
<idno type="ISSN">0360-4012</idno>
<idno type="eISSN">1097-4547</idno>
<imprint>
<date when="2018">2018</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<title>Abstract</title>
<p>Ischemic stroke is devastating and a major cause of morbidity and mortality worldwide. To date, only clot retrieval devices and/or intravenous tissue plasminogen activators (tPA) have been approved by the US‐FDA for the treatment of acute ischemic stroke. Therefore, there is an urgent need to develop an effective treatment for stroke that can have limited shortcomings and broad spectrum of applications. Interferon‐beta (IFN‐β), an endogenous cytokine and a key anti‐inflammatory agent, contributes toward obviating deleterious stroke outcomes. Therefore, exploring the role of IFN‐β may be a promising alternative approach for stroke intervention in the future. In the present review, we have discussed about IFN‐β along with its different mechanistic roles in ischemic stroke. Furthermore, therapeutic approaches targeting the inflammatory cascade with IFN‐β therapy that may be helpful in improving stroke outcome are also discussed.</p>
</div>
</front>
<back>
<div1 type="bibliography">
<listBibl>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<pmc article-type="review-article">
<pmc-dir>properties open_access</pmc-dir>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Neurosci Res</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Neurosci. Res</journal-id>
<journal-id journal-id-type="doi">10.1002/(ISSN)1097-4547</journal-id>
<journal-id journal-id-type="publisher-id">JNR</journal-id>
<journal-title-group>
<journal-title>Journal of Neuroscience Research</journal-title>
</journal-title-group>
<issn pub-type="ppub">0360-4012</issn>
<issn pub-type="epub">1097-4547</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30320448</article-id>
<article-id pub-id-type="pmc">7167007</article-id>
<article-id pub-id-type="doi">10.1002/jnr.24333</article-id>
<article-id pub-id-type="publisher-id">JNR24333</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Minireview</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Minireviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Therapeutic spectrum of interferon‐β in ischemic stroke</article-title>
<alt-title alt-title-type="right-running-head">XXXX</alt-title>
<alt-title alt-title-type="left-running-head">Wanve et al.</alt-title>
</title-group>
<contrib-group>
<contrib id="jnr24333-cr-0001" contrib-type="author">
<name>
<surname>Wanve</surname>
<given-names>Madhuri</given-names>
</name>
<xref ref-type="aff" rid="jnr24333-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib id="jnr24333-cr-0002" contrib-type="author">
<name>
<surname>Kaur</surname>
<given-names>Harpreet</given-names>
</name>
<xref ref-type="aff" rid="jnr24333-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib id="jnr24333-cr-0003" contrib-type="author">
<name>
<surname>Sarmah</surname>
<given-names>Deepaneeta</given-names>
</name>
<xref ref-type="aff" rid="jnr24333-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib id="jnr24333-cr-0004" contrib-type="author">
<name>
<surname>Saraf</surname>
<given-names>Jackson</given-names>
</name>
<xref ref-type="aff" rid="jnr24333-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib id="jnr24333-cr-0005" contrib-type="author">
<name>
<surname>Pravalika</surname>
<given-names>Kanta</given-names>
</name>
<xref ref-type="aff" rid="jnr24333-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib id="jnr24333-cr-0006" contrib-type="author">
<name>
<surname>Vats</surname>
<given-names>Kanchan</given-names>
</name>
<xref ref-type="aff" rid="jnr24333-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib id="jnr24333-cr-0007" contrib-type="author">
<name>
<surname>Kalia</surname>
<given-names>Kiran</given-names>
</name>
<xref ref-type="aff" rid="jnr24333-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib id="jnr24333-cr-0008" contrib-type="author">
<name>
<surname>Borah</surname>
<given-names>Anupom</given-names>
</name>
<xref ref-type="aff" rid="jnr24333-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib id="jnr24333-cr-0009" contrib-type="author">
<name>
<surname>Yavagal</surname>
<given-names>Dileep R.</given-names>
</name>
<xref ref-type="aff" rid="jnr24333-aff-0003">
<sup>3</sup>
</xref>
</contrib>
<contrib id="jnr24333-cr-0010" contrib-type="author">
<name>
<surname>Dave</surname>
<given-names>Kunjan R.</given-names>
</name>
<xref ref-type="aff" rid="jnr24333-aff-0003">
<sup>3</sup>
</xref>
</contrib>
<contrib id="jnr24333-cr-0011" contrib-type="author" corresp="yes">
<name>
<surname>Bhattacharya</surname>
<given-names>Pallab</given-names>
</name>
<contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-2867-1650</contrib-id>
<xref ref-type="aff" rid="jnr24333-aff-0001">
<sup>1</sup>
</xref>
<address>
<email>pallab.bhu@gmail.com</email>
<email>pallab.bhattacharya@niperahm.ac.in</email>
</address>
</contrib>
</contrib-group>
<aff id="jnr24333-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Pharmacology and Toxicology</named-content>
<institution>National Institute of Pharmaceutical Education and Research (NIPER)</institution>
<city>Gandhinagar</city>
<country country="IN">India</country>
</aff>
<aff id="jnr24333-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Cellular and Molecular Neurobiology Laboratory, Department of Life Science and Bioinformatics</named-content>
<institution>Assam University</institution>
<city>Silchar</city>
<country country="IN">India</country>
</aff>
<aff id="jnr24333-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology and Neurosurgery</named-content>
<institution>University of Miami Miller School of Medicine</institution>
<city>Miami</city>
<named-content content-type="country-part">Florida</named-content>
</aff>
<author-notes>
<corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break></break>
Pallab Bhattacharya, National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad, Palaj, Gandhinagar 382355, Gujarat, India.
<break></break>
Email:
<email>pallab.bhu@gmail.com</email>
;
<email>pallab.bhattacharya@niperahm.ac.in</email>
<break></break>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>15</day>
<month>10</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>2</month>
<year>2019</year>
</pub-date>
<volume>97</volume>
<issue>2</issue>
<issue-id pub-id-type="doi">10.1002/jnr.v97.2</issue-id>
<fpage>116</fpage>
<lpage>127</lpage>
<history>
<date date-type="received">
<day>14</day>
<month>6</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>05</day>
<month>9</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>05</day>
<month>9</month>
<year>2018</year>
</date>
</history>
<permissions>
<pmc-comment> © 2019 Wiley Periodicals, Inc. </pmc-comment>
<copyright-statement content-type="article-copyright">© 2018 Wiley Periodicals, Inc</copyright-statement>
<license>
<license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="file:JNR-97-116.pdf"></self-uri>
<abstract id="jnr24333-abs-0001">
<title>Abstract</title>
<p>Ischemic stroke is devastating and a major cause of morbidity and mortality worldwide. To date, only clot retrieval devices and/or intravenous tissue plasminogen activators (tPA) have been approved by the US‐FDA for the treatment of acute ischemic stroke. Therefore, there is an urgent need to develop an effective treatment for stroke that can have limited shortcomings and broad spectrum of applications. Interferon‐beta (IFN‐β), an endogenous cytokine and a key anti‐inflammatory agent, contributes toward obviating deleterious stroke outcomes. Therefore, exploring the role of IFN‐β may be a promising alternative approach for stroke intervention in the future. In the present review, we have discussed about IFN‐β along with its different mechanistic roles in ischemic stroke. Furthermore, therapeutic approaches targeting the inflammatory cascade with IFN‐β therapy that may be helpful in improving stroke outcome are also discussed.</p>
</abstract>
<kwd-group kwd-group-type="author-generated">
<kwd id="jnr24333-kwd-0004">Anti‐inflammatory</kwd>
<kwd id="jnr24333-kwd-0003">cytokines</kwd>
<kwd id="jnr24333-kwd-0002">IFN‐β</kwd>
<kwd id="jnr24333-kwd-0001">stroke</kwd>
</kwd-group>
<funding-group>
<award-group id="funding-0001">
<funding-source>
<institution-wrap>
<institution>Science and Engineering Research Board </institution>
<institution-id institution-id-type="open-funder-registry">10.13039/501100001843</institution-id>
</institution-wrap>
</funding-source>
<award-id>SB/YS/LS-196/2014</award-id>
</award-group>
<award-group id="funding-0002">
<funding-source>NIPER‐Ahmedabad</funding-source>
</award-group>
<award-group id="funding-0003">
<funding-source>Department of Pharmaceuticals, Ministry of Chemical and Fertilizers</funding-source>
</award-group>
<award-group id="funding-0004">
<funding-source>
<institution-wrap>
<institution>International Society for Neurochemistry </institution>
<institution-id institution-id-type="open-funder-registry">10.13039/501100008992</institution-id>
</institution-wrap>
</funding-source>
</award-group>
</funding-group>
<counts>
<fig-count count="3"></fig-count>
<table-count count="2"></table-count>
<page-count count="0"></page-count>
<word-count count="22336"></word-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>February 2019</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.0 mode:remove_FC converted:15.04.2020</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<p content-type="self-citation">
<mixed-citation publication-type="journal" id="jnr24333-cit-1001">
<string-name>
<surname>Wanve</surname>
<given-names>M</given-names>
</string-name>
,
<string-name>
<surname>Kaur</surname>
<given-names>H</given-names>
</string-name>
,
<string-name>
<surname>Sarmah</surname>
<given-names>D</given-names>
</string-name>
, et al.
<article-title>Therapeutic spectrum of interferon‐β in ischemic stroke</article-title>
.
<source xml:lang="en">J Neuro Res</source>
.
<year>2019</year>
;
<volume>97</volume>
:
<fpage>116</fpage>
<lpage>127</lpage>
.
<pub-id pub-id-type="doi">10.1002/jnr.24333</pub-id>
</mixed-citation>
</p>
<fn-group>
<fn id="jnr24333-note-0001">
<p>
<bold>Funding Information</bold>
Science and Engineering Research Board, Grant/Award Number: SB/YS/LS‐196/2014; NIPER‐Ahmedabad; Department of Pharmaceuticals, Ministry of Chemical and Fertilizers; International Society for Neurochemistry</p>
</fn>
</fn-group>
</notes>
</front>
<body id="jnr24333-body-0001">
<sec id="jnr24333-sec-0001">
<label>1</label>
<title>STROKE</title>
<p>Stroke is a global health concern that leads to permanent disability in approximately 30% of survivors (Weinstein, Koerner, & Möller,
<xref rid="jnr24333-bib-0079" ref-type="ref">2010</xref>
). It has devastating complications arising from either a sudden loss of blood supply to the brain (ischemic stroke) or rupturing of blood vessels in the brain (hemorrhagic stroke) (Deb, Sharma, & Hassan,
<xref rid="jnr24333-bib-0016" ref-type="ref">2010</xref>
). Stroke leads to the induction of inflammatory cascade via migration of activated microglia to the ischemic core, worsening its outcomes (Perera et al.,
<xref rid="jnr24333-bib-0063" ref-type="ref">2006</xref>
). The narrow therapeutic window and insufficiency to recover or protect the dying neurons are certain limitations of current treatment strategies for stroke, so there is an urgent need for an alternative approach (Fann et al.,
<xref rid="jnr24333-bib-0021" ref-type="ref">2013</xref>
; Kaur et al.,
<xref rid="jnr24333-bib-0042" ref-type="ref">2018</xref>
). The limitation to improve the aggravated inflammatory condition by currently used thrombolytic agents necessitates newer treatment options for stroke (Carroll,
<xref rid="jnr24333-bib-0011" ref-type="ref">2009</xref>
). Interferon‐β is known to have immunomodulatory and anti‐inflammatory properties and can be explored for improving conditions after stroke (Dhib‐Jalbut & Marks,
<xref rid="jnr24333-bib-0018" ref-type="ref">2010</xref>
). IFN‐β plays a role as an anti‐inflammatory agent through several immune cascades. IFN‐β significantly helps in obviating neuro‐inflammatory conditions of the central nervous system and improves the pathogenesis of many neurological conditions. A report suggested its role in decreasing neuronal cell death and increasing functional recovery attenuating inflammation after stroke onset (Kuo et al.,
<xref rid="jnr24333-bib-0051" ref-type="ref">2016</xref>
).</p>
</sec>
<sec id="jnr24333-sec-0002">
<label>2</label>
<title>INTERFERON</title>
<p>Interferons (IFNs) are signaling proteins belonging to a family of cytokines (Nallar & Kalvakolanu,
<xref rid="jnr24333-bib-0062" ref-type="ref">2014</xref>
). IFNs are actively engaged in altering the cellular immune system against the viral infections of host cells (Fritsch & Weichhart,
<xref rid="jnr24333-bib-0025" ref-type="ref">2016</xref>
). IFNs generally act against extracellular biomolecules via the stimulation of Toll‐like receptors (TLRs) and amplify the antigen presentation to specific T cells. They act by both paracrine and autocrine modes for the regulation of acquired and innate immunity via stimulation of intercellular and intracellular networks providing resistance to certain viral infections and maintenance of normal cell survival and tumor cell death (Le, Genin, Baines, & Hiscott,
<xref rid="jnr24333-bib-0053" ref-type="ref">2000</xref>
).</p>
<sec id="jnr24333-sec-0003">
<label>2.1</label>
<title>Types of interferons and their signaling pathways</title>
<p>Interferons have been classified according to their structural homology and receptor types as type I, II, and III. Type I IFNs include alpha (α), beta (β), delta (δ), epsilon (Ɛ), kappa (κ), and omega (ω). Type‐II IFNs include gamma (γ) and type‐III, also known as IFN‐lambda (λ), have interferon‐like activities (Kopitar‐Jerala,
<xref rid="jnr24333-bib-0046" ref-type="ref">2017</xref>
; Wack, Terczyńska‐Dyla, & Hartmann,
<xref rid="jnr24333-bib-0076" ref-type="ref">2015</xref>
). Type‐I IFNs α and β act by binding to interferon alpha‐receptors (IFNARs). The IFNAR is a heterodimeric transmembrane receptor consisting of two subunits that is, IFNAR1 and IFNAR2 (Sheppard et al.,
<xref rid="jnr24333-bib-0069" ref-type="ref">2003</xref>
). The binding of IFNs α and β with the IFNAR leads to the activation of receptor‐associated protein tyrosine kinases. Janus kinase 1 and tyrosine kinase 2 in turn phosphorylate the signal transducer and activator of transcription 1 (STAT1) and 2 (STAT2). Activation of STAT 1 and 2 is followed by dimerization and translocation into the nucleus and, by combining with IFN‐regulatory factor 9, forms a trimolecular complex called IFN‐stimulated gene factor 3 (ISGF3). This ISGF3 further binds to DNA sequences, which are known as IFN‐stimulated response elements, and directly activates the transcription of ISGs. The signal decays within a period of hours and the STATs are exported back to the cytoplasm for the next signaling process (Figure
<xref rid="jnr24333-fig-0001" ref-type="fig">1</xref>
). Other key regulators of the IFN signaling cascade are the negative regulators which cover different mechanisms that suppress type I IFN‐mediated expressions such as suppressor of cytokines signaling (SOCS) and ubiquitin carboxy‐terminal hydrolase 18 (USP 18) (Kopitar‐Jerala,
<xref rid="jnr24333-bib-0046" ref-type="ref">2017</xref>
; Schreiber & Piehler,
<xref rid="jnr24333-bib-0068" ref-type="ref">2015</xref>
) (Table
<xref rid="jnr24333-tbl-0001" ref-type="table">1</xref>
).</p>
<fig fig-type="Figure" xml:lang="en" id="jnr24333-fig-0001" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Interferon signaling pathway. Binding of IFNs (α and β) with IFNAR (Interferon‐α/β receptor): Activation of receptor‐associated protein tyrosine kinase. (a) Janus kinase‐1. (b) Tyrosine kinase‐2. (c) Signaling pathway through TRIF. These two protein tyrosine kinases start phosphorylation of signal transducer and activator of transcription1 STAT1 & STAT2. Activation of STAT1 & STAT2. Dimerization and translocation of STAT1 & STAT2 to the nucleus. Formation of trimolecular complex together with IFN‐regulatory factor‐9 (IRF‐9) that is, IFN‐stimulated gene factor‐3 (ISGF3). Binding of ISGF‐3 with DNA sequence called as IFN‐stimulated response elements. These IFN‐stimulated response elements activate transcription of ISGs directly and regulate signaling of IFNs. Within hours signal decays and STATs return to cytoplasm for next signaling pathway. TLR 4 mediated IFN‐β activation through TRIF‐dependent pathway via Interferon regulatory factor 3 (IRF‐3) [Colour figure can be viewed at
<ext-link ext-link-type="uri" xlink:href="http://wileyonlinelibrary.com">http://wileyonlinelibrary.com</ext-link>
]</p>
</caption>
<graphic id="nlm-graphic-1" xlink:href="JNR-97-116-g001"></graphic>
</fig>
<table-wrap id="jnr24333-tbl-0001" xml:lang="en" orientation="portrait" position="float">
<label>Table 1</label>
<caption>
<p>Types of human IFN and IFN‐like proteins</p>
</caption>
<table frame="hsides" rules="groups">
<col style="border-right:solid 1px #000000" span="1"></col>
<col style="border-right:solid 1px #000000" span="1"></col>
<col style="border-right:solid 1px #000000" span="1"></col>
<col style="border-right:solid 1px #000000" span="1"></col>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" valign="top" rowspan="1" colspan="1">Ligand types</th>
<th align="left" valign="top" rowspan="1" colspan="1">Names</th>
<th align="left" valign="top" rowspan="1" colspan="1">Receptor chain 1</th>
<th align="left" valign="top" rowspan="1" colspan="1">Receptor chain 2</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">IFN (Type‐I)</td>
<td align="left" rowspan="1" colspan="1">IFN‐α</td>
<td align="left" rowspan="1" colspan="1">IFN‐α R1/IFNAR1</td>
<td align="left" rowspan="1" colspan="1">IFN‐α R2/IFNAR2</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1">IFN‐β</td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1">IFN‐k</td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1">IFN‐ε</td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1">IFN‐ω</td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1">IFN‐v</td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">IFN (Type‐II)</td>
<td align="left" rowspan="1" colspan="1">IFN‐γ</td>
<td align="left" rowspan="1" colspan="1">IFN‐γ R1</td>
<td align="left" rowspan="1" colspan="1">IFN‐γ R2</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">IFN‐like proteins</td>
<td align="left" rowspan="1" colspan="1">IL‐28A</td>
<td align="left" rowspan="1" colspan="1">IL‐28R1</td>
<td align="left" rowspan="1" colspan="1">IL‐10R2</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1">IL‐28B</td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1">IL‐29</td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
</tr>
</tbody>
</table>
<permissions>
<copyright-holder>John Wiley & Sons, Ltd</copyright-holder>
<license>
<license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p>
</license>
</permissions>
</table-wrap>
<sec id="jnr24333-sec-0004">
<label>2.1.1</label>
<title>Role of interferons</title>
<p>Type I IFNs (IFN‐α and IFN‐β) exhibit a wide breadth of biological activities (antiviral, anti‐inflammatory, and anti‐proliferative) (Kuo et al.,
<xref rid="jnr24333-bib-0051" ref-type="ref">2016</xref>
). The latter occurs via cytotoxic stimulation of numerous cells of the immune system such as natural killer cells, monocytes, T cells, macrophages, and dendritic cells. IFNs can also upregulate the cell surface expression of major histocompatibility complex (MHC) antigens and tumor‐associated surface antigens. It helps in the induction or activation of pro‐apoptotic genes and proteins (Bak, Bax, TNF‐related apoptosis‐inducing ligand (TRAIL), and caspases) as well as the repression or reduction of anti‐apoptotic genes such as inhibitor of apoptosis protein (IAP) and B‐cell lymphoma 2 (Bcl‐2), responsible for cell proliferation and differentiation and anti‐angiogenic activity (Pestka,
<xref rid="jnr24333-bib-0064" ref-type="ref">2007</xref>
).</p>
<p>IFNs have been recognized to be deeply implicated in the pathogenesis of several diseases, for example, collagen diseases such as rheumatoid arthritis (Conigliaro et al.,
<xref rid="jnr24333-bib-0013" ref-type="ref">2010</xref>
), systemic lupus erythematosus (SLE) (Gao, Anolik, & Looney,
<xref rid="jnr24333-bib-0026" ref-type="ref">2018</xref>
), multiple sclerosis (Rudick & Goelz,
<xref rid="jnr24333-bib-0066" ref-type="ref">2011</xref>
), insulin‐dependent diabetes mellitus (Qaisar, Jurczyk, & Wang,
<xref rid="jnr24333-bib-0065" ref-type="ref">2018</xref>
), pancreatic cancer (Booy, Hofland, & van Eijck,
<xref rid="jnr24333-bib-0009" ref-type="ref">2015</xref>
), fulminant hepatitis (Borst et al.,
<xref rid="jnr24333-bib-0010" ref-type="ref">2018</xref>
), atherosclerosis (Moss & Ramji,
<xref rid="jnr24333-bib-0061" ref-type="ref">2017</xref>
), and allergic diseases (Gonzales‐van Horn & Farrar,
<xref rid="jnr24333-bib-0031" ref-type="ref">2015</xref>
). IFNs are clinically used in the therapy against viral infections such as hepatitis B and C (Asselah & Marcellin,
<xref rid="jnr24333-bib-0004" ref-type="ref">2018</xref>
; Jaeckel et al.,
<xref rid="jnr24333-bib-0038" ref-type="ref">2001</xref>
) and for different malignancies (Baron et al.,
<xref rid="jnr24333-bib-0007" ref-type="ref">1991</xref>
; Imanishi,
<xref rid="jnr24333-bib-0036" ref-type="ref">1994</xref>
).</p>
<sec id="jnr24333-sec-0005">
<title>Interferon‐β</title>
<p>Interferon‐β (IFN‐β), a broadly expressed cytokine, was approved by the US FDA in the past for the relapsing‐remitting multiple sclerosis (RRMS) treatment for more than a decade (Kuo et al.,
<xref rid="jnr24333-bib-0051" ref-type="ref">2016</xref>
). IFN‐β drives innate immunity, acting in response to pathogenic attack or injury via activation of both pro‐and anti‐inflammatory cytokines. Currently, research is being conducted to find a protective role of IFN‐β in several diseases such as ischemic stroke, subarachnoid hemorrhage, colitis, colorectal cancer (Kotredes, Thomas, & Gamero,
<xref rid="jnr24333-bib-0047" ref-type="ref">2017</xref>
; Kuo et al.,
<xref rid="jnr24333-bib-0051" ref-type="ref">2016</xref>
; Tiebosch et al.,
<xref rid="jnr24333-bib-0074" ref-type="ref">2013</xref>
) along with other conditions (Table
<xref rid="jnr24333-tbl-0002" ref-type="table">2</xref>
) (68), such as anti‐inflammatory (Kuo et al.,
<xref rid="jnr24333-bib-0051" ref-type="ref">2016</xref>
), antiviral (Kraus & Oschmann,
<xref rid="jnr24333-bib-0048" ref-type="ref">2006</xref>
; Samuel,
<xref rid="jnr24333-bib-0067" ref-type="ref">2001</xref>
), immuno modulatory (Kasper & Reder,
<xref rid="jnr24333-bib-0041" ref-type="ref">2014</xref>
), anti‐proliferative (Dierckx et al.,
<xref rid="jnr24333-bib-0019" ref-type="ref">2017</xref>
), anti‐angiogenic (Friedman,
<xref rid="jnr24333-bib-0024" ref-type="ref">2008</xref>
), and cell differentiation (Kraus & Oschmann,
<xref rid="jnr24333-bib-0048" ref-type="ref">2006</xref>
) (see Table
<xref rid="jnr24333-tbl-0002" ref-type="table">2</xref>
).</p>
<table-wrap id="jnr24333-tbl-0002" xml:lang="en" orientation="portrait" position="float">
<label>Table 2</label>
<caption>
<p>Clinical trials of interferon beta‐1b and interferon beta‐1a</p>
</caption>
<table frame="hsides" rules="groups">
<col style="border-right:solid 1px #000000" span="1"></col>
<col style="border-right:solid 1px #000000" span="1"></col>
<col style="border-right:solid 1px #000000" span="1"></col>
<col style="border-right:solid 1px #000000" span="1"></col>
<col style="border-right:solid 1px #000000" span="1"></col>
<col style="border-right:solid 1px #000000" span="1"></col>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" valign="top" rowspan="1" colspan="1">Sr. No</th>
<th align="left" valign="top" rowspan="1" colspan="1">Phase</th>
<th align="left" valign="top" rowspan="1" colspan="1">Status</th>
<th align="left" valign="top" rowspan="1" colspan="1">Condition</th>
<th align="left" valign="top" rowspan="1" colspan="1">Count</th>
<th align="left" valign="top" rowspan="1" colspan="1">References</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="6" rowspan="1">Interferon‐β</td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1">
<italic>Interferon‐β1b</italic>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">1.</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">Completed</td>
<td align="left" rowspan="1" colspan="1">Disseminated Sclerosis</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2.</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">Completed</td>
<td align="left" rowspan="1" colspan="1">Human Immuno‐deficiency Virus Infections (HIV)/Kaposis Sarcoma</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">3.</td>
<td align="left" rowspan="1" colspan="1">I, II</td>
<td align="left" rowspan="1" colspan="1">Completed</td>
<td align="left" rowspan="1" colspan="1">Acute Respiratory Distress Syndrome (ARDS)/Acute Lung Injury (ALI)</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">4.</td>
<td align="left" rowspan="1" colspan="1">II</td>
<td align="left" rowspan="1" colspan="1">Completed</td>
<td align="left" rowspan="1" colspan="1">Disseminated Sclerosis</td>
<td align="left" rowspan="1" colspan="1">III</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">5.</td>
<td align="left" rowspan="1" colspan="1">II</td>
<td align="left" rowspan="1" colspan="1">Completed</td>
<td align="left" rowspan="1" colspan="1">Disseminated Sclerosis/Relapsing‐Remitting Multiple Sclerosis (RRMS)</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">6.</td>
<td align="left" rowspan="1" colspan="1">II</td>
<td align="left" rowspan="1" colspan="1">Completed</td>
<td align="left" rowspan="1" colspan="1">Heart Disease/Prophylaxis of Cardiomyopathy</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">7.</td>
<td align="left" rowspan="1" colspan="1">II</td>
<td align="left" rowspan="1" colspan="1">Completed</td>
<td align="left" rowspan="1" colspan="1">Relapsing‐Remitting Multiple Sclerosis (RRMS)</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">8.</td>
<td align="left" rowspan="1" colspan="1">II</td>
<td align="left" rowspan="1" colspan="1">Completed</td>
<td align="left" rowspan="1" colspan="1">Disseminated Sclerosis</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">9.</td>
<td align="left" rowspan="1" colspan="1">II, III</td>
<td align="left" rowspan="1" colspan="1">Not known</td>
<td align="left" rowspan="1" colspan="1">Disseminated Sclerosis/Relapsing‐Remitting Multiple Sclerosis (RRMS)</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">10.</td>
<td align="left" rowspan="1" colspan="1">II, III</td>
<td align="left" rowspan="1" colspan="1">Recruiting</td>
<td align="left" rowspan="1" colspan="1">Middle East Respiratory Syndrome Coronavirus (MERS‐Coronavirus)</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">11.</td>
<td align="left" rowspan="1" colspan="1">II, III</td>
<td align="left" rowspan="1" colspan="1">Recruiting</td>
<td align="left" rowspan="1" colspan="1">Disseminated Sclerosis</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">12.</td>
<td align="left" rowspan="1" colspan="1">III</td>
<td align="left" rowspan="1" colspan="1">Terminated</td>
<td align="left" rowspan="1" colspan="1">Disseminated Sclerosis</td>
<td align="left" rowspan="1" colspan="1">II</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">13.</td>
<td align="left" rowspan="1" colspan="1">III</td>
<td align="left" rowspan="1" colspan="1">Completed</td>
<td align="left" rowspan="1" colspan="1">Human Immunodeficiency Virus Infections</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">14.</td>
<td align="left" rowspan="1" colspan="1">III</td>
<td align="left" rowspan="1" colspan="1">Completed</td>
<td align="left" rowspan="1" colspan="1">Relapsing‐Remitting Multiple Sclerosis (RRMS</td>
<td align="left" rowspan="1" colspan="1">II</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">15.</td>
<td align="left" rowspan="1" colspan="1">III</td>
<td align="left" rowspan="1" colspan="1">Completed</td>
<td align="left" rowspan="1" colspan="1">Relapsing‐Remitting Multiple Sclerosis (RRMS)</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">16.</td>
<td align="left" rowspan="1" colspan="1">III</td>
<td align="left" rowspan="1" colspan="1">Terminated</td>
<td align="left" rowspan="1" colspan="1">Disseminated Sclerosis</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">17.</td>
<td align="left" rowspan="1" colspan="1">IV</td>
<td align="left" rowspan="1" colspan="1">Withdrawn</td>
<td align="left" rowspan="1" colspan="1">Disseminated Sclerosis</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">18.</td>
<td align="left" rowspan="1" colspan="1">IV</td>
<td align="left" rowspan="1" colspan="1">Completed</td>
<td align="left" rowspan="1" colspan="1">Relapsing‐Remitting Multiple Sclerosis (RRMS)</td>
<td align="left" rowspan="1" colspan="1">IV</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">19.</td>
<td align="left" rowspan="1" colspan="1">IV</td>
<td align="left" rowspan="1" colspan="1">Completed</td>
<td align="left" rowspan="1" colspan="1">Relapsing‐Remitting Multiple Sclerosis (RRMS)</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">20.</td>
<td align="left" rowspan="1" colspan="1">IV</td>
<td align="left" rowspan="1" colspan="1">Terminated</td>
<td align="left" rowspan="1" colspan="1">Relapsing‐Remitting Multiple Sclerosis (RRMS)</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1">
<italic>Interferon‐β1a</italic>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">1.</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">Completed</td>
<td align="left" rowspan="1" colspan="1">Disseminated Sclerosis</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2.</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">Completed</td>
<td align="left" rowspan="1" colspan="1">Healthy volunteers</td>
<td align="left" rowspan="1" colspan="1">II</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">3.</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">Completed</td>
<td align="left" rowspan="1" colspan="1">Cerebrovascular Accidents</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">4.</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">Completed</td>
<td align="left" rowspan="1" colspan="1">Disseminated Sclerosis</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">5.</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">Completed</td>
<td align="left" rowspan="1" colspan="1">Relapsing‐Remitting Multiple Sclerosis (RRMS)</td>
<td align="left" rowspan="1" colspan="1">II</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">6.</td>
<td align="left" rowspan="1" colspan="1">II</td>
<td align="left" rowspan="1" colspan="1">Completed</td>
<td align="left" rowspan="1" colspan="1">Disseminated Sclerosis</td>
<td align="left" rowspan="1" colspan="1">V</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">7.</td>
<td align="left" rowspan="1" colspan="1">II</td>
<td align="left" rowspan="1" colspan="1">Completed</td>
<td align="left" rowspan="1" colspan="1">Asthma Bronchial</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">8.</td>
<td align="left" rowspan="1" colspan="1">II</td>
<td align="left" rowspan="1" colspan="1">Completed</td>
<td align="left" rowspan="1" colspan="1">Alzheimer's Disease (AD)</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">9.</td>
<td align="left" rowspan="1" colspan="1">II</td>
<td align="left" rowspan="1" colspan="1">Completed</td>
<td align="left" rowspan="1" colspan="1">Polyradiculoneuropathy, Chronic Inflammatory Demyelinating</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">10.</td>
<td align="left" rowspan="1" colspan="1">II</td>
<td align="left" rowspan="1" colspan="1">Completed</td>
<td align="left" rowspan="1" colspan="1">Relapsing‐Remitting Multiple Sclerosis (RRMS)</td>
<td align="left" rowspan="1" colspan="1">III</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">11.</td>
<td align="left" rowspan="1" colspan="1">II</td>
<td align="left" rowspan="1" colspan="1">Completed</td>
<td align="left" rowspan="1" colspan="1">Ulcerative Colitis (UC)</td>
<td align="left" rowspan="1" colspan="1">II</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">12.</td>
<td align="left" rowspan="1" colspan="1">II</td>
<td align="left" rowspan="1" colspan="1">Terminated</td>
<td align="left" rowspan="1" colspan="1">Crohn’s Disease (CD)</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">13.</td>
<td align="left" rowspan="1" colspan="1">II</td>
<td align="left" rowspan="1" colspan="1">Withdrawn</td>
<td align="left" rowspan="1" colspan="1">Relapsing‐Remitting Multiple Sclerosis (RRMS)</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">14.</td>
<td align="left" rowspan="1" colspan="1">II, III</td>
<td align="left" rowspan="1" colspan="1">Active Not Recruiting</td>
<td align="left" rowspan="1" colspan="1">Disseminated Sclerosis</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">15.</td>
<td align="left" rowspan="1" colspan="1">II, III</td>
<td align="left" rowspan="1" colspan="1">Recruiting</td>
<td align="left" rowspan="1" colspan="1">Disseminated Sclerosis/Relapsing‐Remitting Multiple Sclerosis (RRMS)</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">16.</td>
<td align="left" rowspan="1" colspan="1">III</td>
<td align="left" rowspan="1" colspan="1">Completed</td>
<td align="left" rowspan="1" colspan="1">Disseminated Sclerosis</td>
<td align="left" rowspan="1" colspan="1">III</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">17.</td>
<td align="left" rowspan="1" colspan="1">III</td>
<td align="left" rowspan="1" colspan="1">Completed</td>
<td align="left" rowspan="1" colspan="1">Chronic Hepatitis‐C Infection</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">18.</td>
<td align="left" rowspan="1" colspan="1">III</td>
<td align="left" rowspan="1" colspan="1">Completed</td>
<td align="left" rowspan="1" colspan="1">Clinically Isolated Syndrome (CIS)</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">19.</td>
<td align="left" rowspan="1" colspan="1">III</td>
<td align="left" rowspan="1" colspan="1">Recruiting</td>
<td align="left" rowspan="1" colspan="1">Respiratory Distress Syndrome, Adult</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">20.</td>
<td align="left" rowspan="1" colspan="1">III</td>
<td align="left" rowspan="1" colspan="1">Terminated</td>
<td align="left" rowspan="1" colspan="1">Relapsing‐Remitting Multiple Sclerosis (RRMS)</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">21.</td>
<td align="left" rowspan="1" colspan="1">III</td>
<td align="left" rowspan="1" colspan="1">Terminated</td>
<td align="left" rowspan="1" colspan="1">Disseminated Sclerosis</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">22.</td>
<td align="left" rowspan="1" colspan="1">III</td>
<td align="left" rowspan="1" colspan="1">Withdrawn</td>
<td align="left" rowspan="1" colspan="1">Relapsing‐Remitting Multiple Sclerosis (RRMS)</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">23.</td>
<td align="left" rowspan="1" colspan="1">IV</td>
<td align="left" rowspan="1" colspan="1">Completed</td>
<td align="left" rowspan="1" colspan="1">Disseminated Sclerosis</td>
<td align="left" rowspan="1" colspan="1">V</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">24.</td>
<td align="left" rowspan="1" colspan="1">IV</td>
<td align="left" rowspan="1" colspan="1">Completed</td>
<td align="left" rowspan="1" colspan="1">Relapsing‐Remitting Multiple Sclerosis (RRMS)</td>
<td align="left" rowspan="1" colspan="1">XII</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">25.</td>
<td align="left" rowspan="1" colspan="1">IV</td>
<td align="left" rowspan="1" colspan="1">Completed</td>
<td align="left" rowspan="1" colspan="1">Clinically Isolated Syndrome (CIS)/Relapsing‐Remitting Multiple Sclerosis (RRMS)</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">26.</td>
<td align="left" rowspan="1" colspan="1">IV</td>
<td align="left" rowspan="1" colspan="1">Terminated</td>
<td align="left" rowspan="1" colspan="1">Relapsing‐Remitting Multiple Sclerosis (RRMS)</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">27.</td>
<td align="left" rowspan="1" colspan="1">IV</td>
<td align="left" rowspan="1" colspan="1">Terminated</td>
<td align="left" rowspan="1" colspan="1">Disseminated Sclerosis</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">28.</td>
<td align="left" rowspan="1" colspan="1">IV</td>
<td align="left" rowspan="1" colspan="1">Withdrawn</td>
<td align="left" rowspan="1" colspan="1">Demyelinating Disorders/Disseminated Sclerosis/Neuritis/Optic Neuritis</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">29.</td>
<td align="left" rowspan="1" colspan="1">IV</td>
<td align="left" rowspan="1" colspan="1">Withdrawn</td>
<td align="left" rowspan="1" colspan="1">Relapsing‐Remitting Multiple Sclerosis (RRMS)</td>
<td align="left" rowspan="1" colspan="1">II</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">30.</td>
<td align="left" rowspan="1" colspan="1">Unavailable</td>
<td align="left" rowspan="1" colspan="1">Withdrawn</td>
<td align="left" rowspan="1" colspan="1">Disseminated Sclerosis</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link>
</td>
</tr>
</tbody>
</table>
<permissions>
<copyright-holder>John Wiley & Sons, Ltd</copyright-holder>
<license>
<license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p>
</license>
</permissions>
</table-wrap>
</sec>
</sec>
</sec>
<sec id="jnr24333-sec-0006">
<label>2.2</label>
<title>Interferon‐beta (IFN‐β): Mechanistic roles and actions</title>
<p>Neurodegeneration is mostly triggered by numerous inflammatory mediators that can lead to neurological pathologies including ischemic stroke (Zipp & Aktas,
<xref rid="jnr24333-bib-0084" ref-type="ref">2006</xref>
). Inflammation is initiated by the release of various inflammatory mediators; activation of intravascular leukocytes helps in the infiltration of immune cells in the CNS (Anrather & Iadecola,
<xref rid="jnr24333-bib-0002" ref-type="ref">2016</xref>
; Kieseier,
<xref rid="jnr24333-bib-0044" ref-type="ref">2011</xref>
). Immune cells migration across the blood–brain barrier (BBB) causes breakdown of the BBB due to the release of numerous cytotoxic agents like cytokines, matrix metalloproteinase, nitric oxide (NO), and reactive oxygen species (ROS), leading to demyelination and axonal injury which are common outcomes of neurodegeneration (Kuo et al.,
<xref rid="jnr24333-bib-0051" ref-type="ref">2016</xref>
). Although the damage caused to neurons is not reparable, immunomodulatory therapies have been reported to decrease inflammation (Markowitz,
<xref rid="jnr24333-bib-0056" ref-type="ref">2007</xref>
). IFN‐β, a polypeptide produced by fibroblasts, attaches to its specific receptor and initiates a complex transcriptional reaction producing a pharmacological response at the site of injury. Markowitz reported that IFN‐β helps in suppressing antigen presentation, decreasing T cell proliferation, and altering cytokine and matrix metalloproteinase expression (Kieseier,
<xref rid="jnr24333-bib-0044" ref-type="ref">2011</xref>
; Markowitz,
<xref rid="jnr24333-bib-0056" ref-type="ref">2007</xref>
).</p>
<p>IFN‐β helps in the elevation of concentration and expression of anti‐inflammatory agents while it down‐regulates the pro‐inflammatory cytokine expression (Kuo et al.,
<xref rid="jnr24333-bib-0051" ref-type="ref">2016</xref>
). A systemic application of IFN‐β may reduce the increased cell count of inflammatory cells across the BBB and help raise nerve growth factor (NGF) levels, ultimately resulting in a dramatic increase in the survival of neurons (Kieseier,
<xref rid="jnr24333-bib-0044" ref-type="ref">2011</xref>
). IFN‐β may also help in raising the CD56
<sup>bright</sup>
natural killer cell count: these cells produce anti‐inflammatory mediators very efficiently and have the capacity to mitigate neuronal inflammation in the peripheral blood circulation. With various mechanistic approaches, IFN‐β manifests to be clinically relevant by reducing lesions, decreasing the risk of sustained disability progression, and decreasing brain atrophy (Kieseier,
<xref rid="jnr24333-bib-0044" ref-type="ref">2011</xref>
).</p>
<p>Cerebral ischemia is responsible for producing various immune cell mediators which can exacerbate ischemic brain injury. These various inflammatory mediators, under certain situations, may induce tolerance to cerebral ischemia. Mediators like proinflammatory cytokines for example, interleukin 1 (IL‐1), tumor necrosis factor (TNF), and damage‐associated molecular patterns (DAMPs) are responsible for the activation of intracellular signaling pathways which mediate stress responses (Anrather & Iadecola,
<xref rid="jnr24333-bib-0002" ref-type="ref">2016</xref>
). Immune cell therapies are highly explored in not only preclinical but also clinical settings for various acute injuries related with the CNS, including stroke (Bang,
<xref rid="jnr24333-bib-0006" ref-type="ref">2016</xref>
; George & Steinberg,
<xref rid="jnr24333-bib-0029" ref-type="ref">2015</xref>
). IFN‐β is immunomodulatory and helps regulate the function of immune cells in ischemic stroke.</p>
<p>IFN‐β modulates antigen presenting cells (APCs) to reduce antigen presentation and stimulation of T cells (Jiang et al.,
<xref rid="jnr24333-bib-0039" ref-type="ref">1995</xref>
). IFN‐β directly affects T cells and inhibits adhesion of molecules like intercellular adhesion molecule (ICAM) and vascular adhesion molecule (VCAM) to the BBB and passage through the same (Dhib‐Jalbut & Marks,
<xref rid="jnr24333-bib-0018" ref-type="ref">2010</xref>
). B cells secrete inflammatory mediators that are responsible for stimulating plasma cells to produce immunoglobulins (IGs) in the cerebrospinal fluid (CSF) (Dalakas,
<xref rid="jnr24333-bib-0015" ref-type="ref">2008</xref>
). B cell activating factor (BAFF), belonging to the TNF family, is upregulated in the blood (Krumbholz et al.,
<xref rid="jnr24333-bib-0049" ref-type="ref">2008</xref>
) and is crucial for maintaining B cells level at the inflammation site and can aggravate local inflammation by facilitating B cell survival (Krumbholz et al.,
<xref rid="jnr24333-bib-0050" ref-type="ref">2005</xref>
). IFN‐β modulates B‐cell function which can alter antigen presentation. Expression of MHC II on B cells is reduced post‐therapy with the help of IFN‐β through a decrease in CD80 expression that inhibits antigen presentation to CD8+T cells (Genç, Dona, & Reder,
<xref rid="jnr24333-bib-0028" ref-type="ref">1997</xref>
; Jiang et al.,
<xref rid="jnr24333-bib-0039" ref-type="ref">1995</xref>
). IFN‐β treatment results in the upregulation of CD86 expressing B cells and contributes to the reduction of type 1 T helper (Th1) cell secretion of inflammatory cytokines (Huang, Ito, Dangond, & Dhib‐Jalbut,
<xref rid="jnr24333-bib-0035" ref-type="ref">2013</xref>
). Levels of BAFF are also upregulated in blood leukocytes and serum with IFN‐β therapy, showing elevated B cell function (Krumbholz et al.,
<xref rid="jnr24333-bib-0049" ref-type="ref">2008</xref>
). With the correct combination of stimuli, it can lead to increased B cell secretion of anti‐inflammatory cytokines like IL‐8 and IL‐10, suggesting that IFN‐β can increase CD4 and CD8 regulatory T cells along with regulatory B cells (Meinl, Krumbholz, & Hohlfeld,
<xref rid="jnr24333-bib-0059" ref-type="ref">2006</xref>
).</p>
</sec>
</sec>
<sec id="jnr24333-sec-0007">
<label>3</label>
<title>ISCHEMIC STROKE AND INTERFERON‐β: CROSSTALK</title>
<sec id="jnr24333-sec-0008">
<label>3.1</label>
<title>Ischemic cascade</title>
<p>Cell death following brain ischemia is mediated by a diverse group of etiologies such as severe focal hypoperfusion that eventually results into excitotoxicity and oxidative damage (Lakhan, Kirchgessner, & Hofer,
<xref rid="jnr24333-bib-0052" ref-type="ref">2009</xref>
). These events are responsible for causing microvascular injury, BBB dysfunction, and elicit inflammation after ischemia. Events of such kind worsen the primary injury and may result in severe cerebral damage. The extent of permanent cerebral damage relies upon different factors such as ischemic duration, infarct volume, along with the auto‐repairing capability of the brain (Dirnagl, Iadecola, & Moskowitz,
<xref rid="jnr24333-bib-0020" ref-type="ref">1999</xref>
; Lakhan et al.,
<xref rid="jnr24333-bib-0052" ref-type="ref">2009</xref>
).</p>
<p>The responses after inflammatory cascade that worsen the cerebral injury post‐ischemia is an interesting target for therapeutics, as inflammation increases over time and is strongly involved in the exacerbation of neuronal outcomes (Jin, Yang, & Li,
<xref rid="jnr24333-bib-0040" ref-type="ref">2010</xref>
). It has been reported that post‐ischemia, systemically applied IFN‐β helps in attenuating brain infarct progression (Veldhuis et al.,
<xref rid="jnr24333-bib-0075" ref-type="ref">2003</xref>
).</p>
<p>During the sub‐acute phase of ischemia, resident microglial cells (MGs) and peripheral inflammatory cells infiltrate into the surrounding and core region of the infarct area of the brain, leading to secondary neurodegeneration (Weinstein et al.,
<xref rid="jnr24333-bib-0079" ref-type="ref">2010</xref>
). The onset of ischemia is mainly linked with the extravasation of plasma‐derived protein, bioactive phospholipids, BBB disruption, and prompt resident MG activation and infiltration into the ischemic site. These multifarious events lead to the activation of pro‐inflammatory cytokines like chemokines (C‐C motif) ligand 2 (CCL2), chemokine (C‐C motif) ligand 3 (CCL3), TNF‐α, IL‐1b, and endogenous NO release at the injury site, culminating in neuronal death (Denes, Thornton, Rothwell, & Allan,
<xref rid="jnr24333-bib-0017" ref-type="ref">2010</xref>
; Weinstein et al.,
<xref rid="jnr24333-bib-0079" ref-type="ref">2010</xref>
).</p>
</sec>
<sec id="jnr24333-sec-0009">
<label>3.2</label>
<title>Neuroprotective role of IFN‐β in Ischemic stroke</title>
<p>CNS inflammation induced due to ischemic conditions plays an essential role in stroke pathophysiology and exacerbates infarct formation at the injury site (Amantea et al.,
<xref rid="jnr24333-bib-0001" ref-type="ref">2015</xref>
; Benakis, Garcia‐Bonilla, Iadecola, & Anrather,
<xref rid="jnr24333-bib-0008" ref-type="ref">2015</xref>
; Kawabori & Yenari,
<xref rid="jnr24333-bib-0043" ref-type="ref">2015</xref>
). IFN‐β markedly reduces infarct size by inhibition of the production of inflammatory cytokines such as IL‐6, IL‐23p19, IL‐1b, and TNF‐α; all of these cytokines are found to be increased in the ipsilateral part of the ischemic brain (Kuo et al.,
<xref rid="jnr24333-bib-0051" ref-type="ref">2016</xref>
) (Figure
<xref rid="jnr24333-fig-0002" ref-type="fig">2</xref>
). Endogenous IFN‐β signaling limits local inflammation, regulates peripheral immune cells, and, thereby, may contribute positively to stroke outcome (Inácio et al.,
<xref rid="jnr24333-bib-0037" ref-type="ref">2015</xref>
).</p>
<fig fig-type="Figure" xml:lang="en" id="jnr24333-fig-0002" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<p>Mechanism of action of IFN‐β. (a) After ischemic injury, immune cells like mast cells, macrophages, and neutrophils from the circulation release the inflammatory cytokines. These inflammatory cytokines include IL‐6, IL‐4, IL‐1B, IL‐23p9, and TNF‐α. At ischemic injury site, there is over‐expression of these inflammatory cytokines. These overexpressed inflammatory cytokines lead to CNS inflammation. Increased CNS inflammation results in infarct formation in the brain. IFN‐β helps in suppressing overexpressed inflammatory cytokines and ultimately helps in reducing the brain infarct in ischemic brain. (b) After an ischemic injury on the ipsilateral side of the hemisphere, there are increased expressions of IBA1 (specifically expressed in microglial cells (MGs), helps in MG regulation) in the cortex. Increased IBA1 results in the transformation of resting MGs to reactive MGs. Reactive MGs influence release of inflammatory cytokines, for example, IL‐6, IL‐4, IL‐1B, IL‐23p9, and TNF‐α leads to cytotoxicity which in turn results in infarct formation in the brain at the injury site. IFN‐β inhibits upregulated IBA1 expression in the cortex of ipsilateral side and reduces the MG activation in the ischemic brain [Colour figure can be viewed at
<ext-link ext-link-type="uri" xlink:href="http://wileyonlinelibrary.com">http://wileyonlinelibrary.com</ext-link>
]</p>
</caption>
<graphic id="nlm-graphic-3" xlink:href="JNR-97-116-g002"></graphic>
</fig>
<p>Rapidly activated MGs in response to ischemic injury are a major factor for the production of inflammatory mediators and increased phagocytosis. Activated MGs trigger innate immune responses followed by increased production of matrix metalloproteinase (MMPs), leading to BBB damage. These inflammatory mediators cause various cytotoxic effects due to the increased expression of inflammatory cytokines at the ischemic site (Benakis et al.,
<xref rid="jnr24333-bib-0008" ref-type="ref">2015</xref>
; Xia, Han, Huang, & Ying,
<xref rid="jnr24333-bib-0081" ref-type="ref">2010</xref>
). Recent findings report that during cerebral ischemia, activated MGs exhibit a high level of ionized calcium‐binding adapter molecule 1 (IBA1) expression, confirmed by confocal images showing round and amoeboid shaped morphology with very short processes and bigger soma in the cortex of the ipsilateral hemisphere (Kuo et al.,
<xref rid="jnr24333-bib-0051" ref-type="ref">2016</xref>
). IFN‐β treatment helps in the suppression of lBA1 expression by reducing MG activation at the site of injury, there by showing ramified morphology with longitudinally branched and smaller soma. Kuo et al. found that IFN‐β’s inhibitory effect on activation of MG is due to a reduction in the expression of pro‐inflammatory cytokines interleukin 23p19 (IL‐23p19), IL‐1b, IL‐6, and TNF‐α at the site of infarct (Kuo et al.,
<xref rid="jnr24333-bib-0051" ref-type="ref">2016</xref>
) (Figure
<xref rid="jnr24333-fig-0002" ref-type="fig">2</xref>
).</p>
<p>A study carried out by Cruz et al. reported that IFN‐β requires IFN regulatory factor 2 binding protein 2 (IRF2BP2) to limit ischemic stroke injury. Mice lacking IRF2BP2‐deficient microglia/macrophages lost the anti‐inflammatory property of IFN‐β, which failed to protect them from ischemic injuries (Cruz et al.,
<xref rid="jnr24333-bib-0014" ref-type="ref">2017</xref>
). Recent work has identified that TLRs and type 1 IFN signaling mediate neuroprotection in both ischemia/reperfusion and ischemic preconditioning (IPC) (McDonough et al.,
<xref rid="jnr24333-bib-0057" ref-type="ref">2017</xref>
). It has been reported that in a mouse model of ischemic injury type 1, IFN signaling is essential for IPC‐directed neuroprotection in white matter (Hamner et al.,
<xref rid="jnr24333-bib-0032" ref-type="ref">2015</xref>
) and gray matter (Stevens et al.,
<xref rid="jnr24333-bib-0072" ref-type="ref">2011</xref>
). McDonough et al. proposed that during ischemia/reperfusion injury MGs lead to the activation of endogenous neuroprotection pathways which are dependent on the IFN‐stimulated genes (ISGs) response (McDonough & Weinstein,
<xref rid="jnr24333-bib-0058" ref-type="ref">2016</xref>
). Wang et al. (
<xref rid="jnr24333-bib-0077" ref-type="ref">2017</xref>
) reported that by promoting expression of TIR‐domain containing adapter‐inducing interferon‐β (TRIF) with the compound Dexmedetomidine improved stroke recovery, supporting the beneficial effect of interferon‐beta in ischemic stroke (Wang et al.,
<xref rid="jnr24333-bib-0077" ref-type="ref">2017</xref>
).</p>
<p>Experimental preconditioning models are robust and primarily focus on neuroprotective actions (Gesuete et al.,
<xref rid="jnr24333-bib-0030" ref-type="ref">2012</xref>
). Gesuete et al., uncovered the protective preconditioning effect of polyinosinic polycytidylic acid (poly‐ICLC) against cerebral ischemic injury. They found that treatment with poly‐ICLC in in vitro and in vivo ischemia models induced IFN‐β mRNA expression and type I IFN signaling in brain microvascular endothelial cells, which attenuated BBB dysfunction and was required for neuroprotection against ischemic injury (Gesuete et al.,
<xref rid="jnr24333-bib-0030" ref-type="ref">2012</xref>
).</p>
<p>During ischemic injury, chemokine induction enhances the peripheral immune cell recruitment to the ischemic brain. Chemokines, including monocyte chemoattractant protein‐1 (MCP‐1), macrophage inflammatory protein‐1α (MIP‐1α), CCL2, and CCL3 are essential in the recruitment of monocytes/macrophage, while Chemokine (C‐X‐C motif) ligand 3 (CXCL3) is essential for neutrophil recruitment (Kuo et al.,
<xref rid="jnr24333-bib-0051" ref-type="ref">2016</xref>
). These are induced to greater levels in the ischemic brain (Hori et al.,
<xref rid="jnr24333-bib-0034" ref-type="ref">2012</xref>
; Wolinski & Glabinski,
<xref rid="jnr24333-bib-0080" ref-type="ref">2013</xref>
; Zaremba, Ilkowski, & Losy,
<xref rid="jnr24333-bib-0082" ref-type="ref">2006</xref>
). Minami et al. reported that the chemokine MCP‐1/CCL2 binding to its respective receptor CCR2 expressed on the brain endothelial surface, leads to dynamic reorganization of the actin cytoskeleton and structural alteration of tight junctions (TJs). This causes a gradual morphological change which was characterized with an upregulated vascular permeability (Stamatovic, Keep, Kunkel, & Andjelkovic,
<xref rid="jnr24333-bib-0071" ref-type="ref">2003</xref>
). The upregulated or increased vascular permeability leads to the formation of brain edema and is found to be a major reason for death with severe infarction (Ayata & Ropper,
<xref rid="jnr24333-bib-0005" ref-type="ref">2002</xref>
; Minami, Katayama, & Satoh,
<xref rid="jnr24333-bib-0060" ref-type="ref">2006</xref>
) (Figure
<xref rid="jnr24333-fig-0003" ref-type="fig">3</xref>
).</p>
<fig fig-type="Figure" xml:lang="en" id="jnr24333-fig-0003" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<p>Mechanism of action of IFN‐β.
<bold>(</bold>
a) Ischemic injury followed by reperfusion. Within hours of ischemia, upregulation of adhesion molecules expression (e.g., ICAM‐1, VCAM‐1, and E‐selectin,) on the brain endothelial surface. These upregulated adhesion molecules increase the influx of inflammatory cells (e.g., monocytes, neutrophils, B cells, and T cells) to the ischemic brain, causing Infarct formation. IFN‐β reduces the upregulated adhesion molecule expression (e.g., ICAM‐1, VCAM‐1, and E‐selectin) and helps in reducing the infarct formation by decreasing inflammatory cell influx into the brain. (b) After ischemic injury, resting microglial cells are activated and increase the release of matrix metalloproteinase 9 (MMP‐9), tumor necrosis factor α (TNF‐α), monocyte chemoattractant protein‐1 (MCP‐1), interleukin 1B (IL‐1B), IL‐8 which facilitate inflammatory cellinfiltration (monocytes, neutrophils, B cells, and T cells) at the injury site in the brain. Increased infiltration of inflammatory cells compromises the blood–brain barrier (BBB) integrity and leads to secondary brain injury, responsible for increased infarct area in the brain. IFN‐β impairs the ischemia‐induced chemokine (C‐C motif) ligand 3 (CCL3), Chemokine (C‐X‐C motif) ligand 3 (CXCL3), and MMP‐9 expressions and helps to reduce brain infarct. (c) Ischemic injury is followed with reperfusion. Reperfusion increases the peripheral immune cell infiltration (CD45hiCD11b+, CD11b+Ly6G+, CD4+, γδ T Cells) at brain injury and leads to BBB compromise; it leads to BBB disruption and secondary brain injury, results in infarct formation in the brain. IFN‐β lowers the number of infiltrating cells that is, CD45hiCD11b+, CD11b+Ly6G+, CD4+, γδ T Cells in ipsilateral side of the brain and shows a protective role in ischemic stroke by decreasing BBB disruption [Colour figure can be viewed at
<ext-link ext-link-type="uri" xlink:href="http://wileyonlinelibrary.com">http://wileyonlinelibrary.com</ext-link>
]</p>
</caption>
<graphic id="nlm-graphic-5" xlink:href="JNR-97-116-g003"></graphic>
</fig>
<p>Matrix metallopeptidase‐9 (MMP‐9), released throughout the course of ischemic injury, increases BBB permeability via degradation of extracellular matrix (ECM), TJs in brain endothelium facilitate the inflammatory immune cell infiltration into the CNS (Chaturvedi & Kaczmarek,
<xref rid="jnr24333-bib-0012" ref-type="ref">2014</xref>
; Lakhan et al.,
<xref rid="jnr24333-bib-0052" ref-type="ref">2009</xref>
). Scientists have reported the significant effect of IFN‐β on the production of MMP‐9 and chemokines in MG, a major producer of inflammatory cytokines implicated as a mediator of neuroinflammation (Kuo et al.,
<xref rid="jnr24333-bib-0051" ref-type="ref">2016</xref>
). It was found that in the ischemic brain, there is a dramatic increase in the expression of CCL3, CXCL3, and MMP‐9 in the ipsilateral part but not in the contralateral part of the brain. IFN‐β treatment helps in reducing the expression of CCL3, CXCL3, and MMP. Kuo et al., have carried out a study to find IFN‐β’s inhibitory effect lipopolysaccharide (LPS)‐induced primary MGs. Their results showed that IFN‐β decreased the expression of CCL3, CXCL3, and MMP‐9 in LPS‐activated MGs in a significant manner (Kuo et al.,
<xref rid="jnr24333-bib-0051" ref-type="ref">2016</xref>
) (Figure
<xref rid="jnr24333-fig-0003" ref-type="fig">3</xref>
).</p>
<p>Cerebral ischemic injury followed by reperfusion is mainly responsible for infiltration of peripheral immune cells consisting of T cells, neutrophils, and monocytes/macrophages, resulting in secondary brain injury eventually responsible for increasing the degree of brain infarction (Benakis et al.,
<xref rid="jnr24333-bib-0008" ref-type="ref">2015</xref>
; Wang, Tang, & Yenari,
<xref rid="jnr24333-bib-0078" ref-type="ref">2007</xref>
). Scientists have also reported that throughout the course of ischemic injury, there is a significant rise in various cell counts including CD11b+Ly6G+ neutrophils and CD45hiCD11b+ monocytes/macrophages in the ipsilateral part of the ischemic brain. In addition, they found that IFN‐β treatment significantly helps in lowering the levels of these cells (Kuo et al.,
<xref rid="jnr24333-bib-0051" ref-type="ref">2016</xref>
) (Figure
<xref rid="jnr24333-fig-0003" ref-type="fig">3</xref>
).</p>
<p>As per previous reports, both CD4+T cells and γδ T cells also playa pathogenic role in ischemic stroke (Gelderblom, Arunachalam, & Magnus,
<xref rid="jnr24333-bib-0027" ref-type="ref">(2014)</xref>
; Shichita et al.,
<xref rid="jnr24333-bib-0070" ref-type="ref">2009</xref>
). There is arise in the numbers of CD4+T cells and γδT cells in the ischemic brain and this leads to the BBB breakdown and increased infarct size associated with induction of MMP3 and MMP9. IFN‐β treatment reduces both CD4+T cell and γδT cell numbers and decreases the infarct size. IFN‐β treatment suppresses the infiltration of various peripheral immune cells like neutrophils, macrophages/monocytes, and CD4+T cells and γδT cells, providing a protective role in ischemic stroke (Kuo et al.,
<xref rid="jnr24333-bib-0051" ref-type="ref">2016</xref>
) (Figure
<xref rid="jnr24333-fig-0003" ref-type="fig">3</xref>
).</p>
<p>During ischemia, inflammatory processes lead to migration of peripheral blood leukocytes into brain parenchyma, regulated by the adhesion molecules. Adhesion molecules including E‐selectin, P‐selectin, ICAM‐1, and VCAM‐1 are expressed on the activated brain endothelial cell surface and are upregulated after ischemia. They are responsible for facilitating the influx of inflammatory cells and conferring BBB breakdown. Reports suggest that within hours of reperfusion in the middle cerebral artery occlusion/reperfusion (MCAO/R) model in rats, adhesion molecules were found to be upregulated in brain endothelial cells (Kuo et al.,
<xref rid="jnr24333-bib-0051" ref-type="ref">2016</xref>
; Lindsberg, Carpe, Paetau, Karjalainen‐Lindsberg, & Kaste,
<xref rid="jnr24333-bib-0054" ref-type="ref">1996</xref>
; Zhang, Chopp, Zhang, Jiang, & Powers,
<xref rid="jnr24333-bib-0083" ref-type="ref">1998</xref>
). Kuo et al. studied that 24‐hr post‐ischemia, there is a significant rise in ICAM‐1 and E‐selectin in the ischemic part of the brain. Further treatment with IFN‐β helps in reducing upregulated ICAM‐1 and E‐selectin in the ipsilateral hemispheres of animals induced with ischemic stroke. Also, there is an increase in VCAM‐1 expression in ischemic stroke, but IFN‐β treatment has not shown any effect on its expression (Kuo et al.,
<xref rid="jnr24333-bib-0051" ref-type="ref">2016</xref>
). They also studied IFN‐β effect on endothelial cell lines bEnd.3. Activation of bEnd.3 cell lines with TNF‐α upregulates ICAM‐1 and E‐selectin at both levels that is, at the genetic level and protein level. They found that IFN‐β treatment helps to obviate TNF‐α‐induced P‐selectin, ICAM‐1, and E‐selectin upregulation but failed inattenuating VCAM‐1 expression which is induced due to TNF‐α on the surface of the cell (Kuo et al.,
<xref rid="jnr24333-bib-0051" ref-type="ref">2016</xref>
; Suárez, Wang, Manes, & Pober,
<xref rid="jnr24333-bib-0073" ref-type="ref">2010</xref>
) (Figure
<xref rid="jnr24333-fig-0003" ref-type="fig">3</xref>
). However, the beneficial effect of IFN‐β to counteract ischemic stroke injury remains controversial. It was reported by Maier et al. that IFN‐β failed to protect ischemic injury in a model of transient focal stroke (Maier, Yu, Nishi, Lathrop, & Chan,
<xref rid="jnr24333-bib-0055" ref-type="ref">2006</xref>
).</p>
<sec id="jnr24333-sec-0010">
<label>3.2.1</label>
<title>Limitations of IFN‐β therapy in ischemic stroke</title>
<p>Since the discovery of IFNs, IFN has progressed from a poorly understood antiviral substance to being FDA‐approved for the treatment of five disorders (Baron et al.,
<xref rid="jnr24333-bib-0007" ref-type="ref">1991</xref>
)
<bold>.</bold>
We have discussed the various mechanisms of IFN
<bold></bold>
β and its therapeutic potential. However, certain side effects limit the use of IFN‐β (Pestka,
<xref rid="jnr24333-bib-0064" ref-type="ref">2007</xref>
). Although IFN‐β is usually safe and well tolerated, it causes certain adverse effects. IFNs not only cause local adverse events but systemic adverse reactions as well (Kolb‐Mäurer, Goebeler, & Mäurer,
<xref rid="jnr24333-bib-0045" ref-type="ref">2015</xref>
). After treatment with IFN‐β, patients have exhibited fatigue, myalgia, headache, malaise, and joint pain (Pestka,
<xref rid="jnr24333-bib-0064" ref-type="ref">2007</xref>
). Depression has been reported in patients with no prior psychiatric history following IFN‐β therapy (Fragoso et al.,
<xref rid="jnr24333-bib-0022" ref-type="ref">2010</xref>
). Reduced doses of IFN‐β have elicited severe depression and altered tolerability, resulting in discontinuation of treatment (Asnis & De La Garza II,
<xref rid="jnr24333-bib-0003" ref-type="ref">2005</xref>
). Few studies have demonstrated that endogenous molecules like melatonin, a potent antioxidant and a regulator of circadian rhythm, maybe helpful in mitigating the depressive symptoms associated with IFN‐β (Hansen, Danielsen, Hageman, Rosenberg, & Gögenur,
<xref rid="jnr24333-bib-0033" ref-type="ref">2014</xref>
). Also, it has been reported that therapy of IFN‐β in combination with L‐methyl folate or S‐adenosyl methionine has varying degrees of outcomes in monotherapy or augmentation therapy for depression (Franscina Pinto & Andrade,
<xref rid="jnr24333-bib-0023" ref-type="ref">2016</xref>
). However, till date, no studies have been examined in therapeutic treatment of the IFN‐β‐related depressive disorder and should, therefore, be appraised as a possibility in future studies. Thus, IFN‐β therapy may serve as a substantial therapy for the treatment of acute ischemic stroke if the side effects of IFN‐β can be reduced and prevented.</p>
</sec>
</sec>
</sec>
<sec id="jnr24333-sec-0011">
<label>4</label>
<title>CONCLUSION</title>
<p>Inflammation and immunity are an essential and fundamental parts of the pathogenesis initiated by ischemic and reperfusion injury. Inflammatory cascade is responsible for initiation of early molecular events caused due to blood vessel occlusion and culminates in brain invasion by various inflammatory cells. CNS inflammation, cytotoxicity, BBB disruption, and peripheral immune cell infiltration at the injury site play important roles in secondary brain injury and lead to increased brain infarct. IFN‐β may play protective and multiphasic roles after ischemic stroke. This review focused on the neuroprotective role of IFN‐β in ischemic stroke. As there is a growing body of evidence indicating that inflammatory mediators are predominantly deleterious in the primary phase after ischemic stroke, IFN‐β may be a promising treatment option against ischemic stroke and may be salutary for future adjuvant therapy. With these preclinical findings, IFN‐β has entered the clinical level as a therapeutic agent for ischemic stroke. However, some more substantial findings are required to be carried out in the future for better understanding of ischemic stroke in relation with CNS inflammation, cytotoxicity, BBB dysfunction, and the therapeutic potential of IFN‐β in ischemic stroke.</p>
</sec>
<sec sec-type="COI-statement" id="jnr24333-sec-0012">
<title>CONFLICT OF INTEREST</title>
<p>The authors have no conflict of interest to declare.</p>
</sec>
<sec id="jnr24333-sec-0013">
<title>AUTHOR CONTRIBUTIONS</title>
<p>
<italic>Conceptualization</italic>
, M.W., H.K., D.S. and P.B.;
<italic>Methodology</italic>
, M.W., H.K., D.S. and P.B.;
<italic>Writing – Original Draft</italic>
, H.K., D.S., J.S., K.P., K.V., K.K., A.B., D.Y., K.D., P.B.;
<italic>Visualization</italic>
, M.W., H.K., D.S., D.Y., K.D., A.B. and P.B.;
<italic>Writing – Review & Editing</italic>
, M.W., H.K., D.S., J.S., A.B., K.K., K.D. and P.B.</p>
</sec>
</body>
<back>
<ack id="jnr24333-sec-0014">
<title>ACKNOWLEDGMENT</title>
<p>Authors acknowledge Department of Science and Technology (DST), Govt. of India for their financial support through a grant (SB/YS/LS‐196/2014), International Society for Neurochemistry (ISN) Return Home grant, Department of Pharmaceuticals, Ministry of Chemical and Fertilizers, Govt. of India and National Institute of Pharmaceutical Education and Research (NIPER) Ahmedabad, Gandhinagar, India. Authors also want to express their thanks to Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA and the Director, NIPER Ahmedabad, for providing necessary support.</p>
</ack>
<ref-list content-type="cited-references" id="jnr24333-bibl-0001">
<title>REFERENCES</title>
<ref id="jnr24333-bib-0001">
<mixed-citation publication-type="journal" id="jnr24333-cit-0001">
<string-name>
<surname>Amantea</surname>
,
<given-names>D.</given-names>
</string-name>
,
<string-name>
<surname>Micieli</surname>
,
<given-names>G.</given-names>
</string-name>
,
<string-name>
<surname>Tassorelli</surname>
,
<given-names>C.</given-names>
</string-name>
,
<string-name>
<surname>Cuartero</surname>
,
<given-names>M. I.</given-names>
</string-name>
,
<string-name>
<surname>Ballesteros</surname>
,
<given-names>I.</given-names>
</string-name>
,
<string-name>
<surname>Certo</surname>
,
<given-names>M.</given-names>
</string-name>
, …
<string-name>
<surname>Bagetta</surname>
,
<given-names>G.</given-names>
</string-name>
(
<year>2015</year>
).
<article-title>Rational modulation of the innate immune system for neuroprotection in ischemic stroke</article-title>
.
<source xml:lang="en">Frontiers in Neuroscience</source>
,
<volume>9</volume>
,
<fpage>147</fpage>
<pub-id pub-id-type="doi">10.3389/fnins.2015.00147</pub-id>
<pub-id pub-id-type="pmid">25972779</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0002">
<mixed-citation publication-type="journal" id="jnr24333-cit-0002">
<string-name>
<surname>Anrather</surname>
,
<given-names>J.</given-names>
</string-name>
, &
<string-name>
<surname>Iadecola</surname>
,
<given-names>C.</given-names>
</string-name>
(
<year>2016</year>
).
<article-title>Inflammation and stroke: An overview</article-title>
.
<source xml:lang="en">Neurotherapeutics</source>
,
<volume>13</volume>
(
<issue>4</issue>
),
<fpage>661</fpage>
<lpage>670</lpage>
.
<pub-id pub-id-type="doi">10.1007/s13311-016-0483-x</pub-id>
<pub-id pub-id-type="pmid">27730544</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0003">
<mixed-citation publication-type="journal" id="jnr24333-cit-0003">
<string-name>
<surname>Asnis</surname>
,
<given-names>G. M.</given-names>
</string-name>
, &
<string-name>
<surname>De La Garza II</surname>
,
<given-names>R</given-names>
</string-name>
. (
<year>2005</year>
).
<article-title>Interferon‐induced depression: Strategies in treatment</article-title>
.
<source xml:lang="en">Progress in Neuro‐Psychopharmacology and Biological Psychiatry</source>
,
<volume>29</volume>
(
<issue>5</issue>
),
<fpage>808</fpage>
<lpage>818</lpage>
.
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2005.03.006</pub-id>
<pub-id pub-id-type="pmid">15907352</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0004">
<mixed-citation publication-type="book" id="jnr24333-cit-0004">
<string-name>
<surname>Asselah</surname>
,
<given-names>T</given-names>
</string-name>
.,
<string-name>
<surname>Marcellin</surname>
,
<given-names>P</given-names>
</string-name>
., &
<string-name>
<surname>Schinazi</surname>
,
<given-names>R. F</given-names>
</string-name>
. (
<year>2018</year>
).
<chapter-title>Chronic HBV infection: Interferon therapy and long‐term outcomes</chapter-title>
<source xml:lang="en">Hepatitis B virus and liver disease</source>
(pp.
<fpage>181</fpage>
<lpage>191</lpage>
).
<publisher-loc>Singapore</publisher-loc>
:
<publisher-name> Springer</publisher-name>
<ext-link ext-link-type="uri" xlink:href="https://doi:10.1111/liv.13673">https://doi:10.1111/liv.13673</ext-link>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0005">
<mixed-citation publication-type="journal" id="jnr24333-cit-0005">
<string-name>
<surname>Ayata</surname>
,
<given-names>C.</given-names>
</string-name>
, &
<string-name>
<surname>Ropper</surname>
,
<given-names>A. H.</given-names>
</string-name>
(
<year>2002</year>
).
<article-title>Ischaemic brain oedema</article-title>
.
<source xml:lang="en">Journal of Clinical Neuroscience</source>
,
<volume>9</volume>
(
<issue>2</issue>
),
<fpage>113</fpage>
<lpage>124</lpage>
.
<pub-id pub-id-type="doi">10.1054/jocn.2001.1031</pub-id>
<pub-id pub-id-type="pmid">11922696</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0006">
<mixed-citation publication-type="journal" id="jnr24333-cit-0006">
<string-name>
<surname>Bang</surname>
,
<given-names>O. Y.</given-names>
</string-name>
(
<year>2016</year>
).
<article-title>Clinical trials of adult stem cell therapy in patients with ischemic stroke</article-title>
.
<source xml:lang="en">Journal of Clinical Neurology</source>
,
<volume>12</volume>
(
<issue>1</issue>
),
<fpage>14</fpage>
<lpage>20</lpage>
.
<pub-id pub-id-type="doi">10.3988/jcn.2016.12.1.14</pub-id>
<pub-id pub-id-type="pmid">26610894</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0007">
<mixed-citation publication-type="journal" id="jnr24333-cit-0007">
<string-name>
<surname>Baron</surname>
,
<given-names>S.</given-names>
</string-name>
,
<string-name>
<surname>Tyring</surname>
,
<given-names>S. K.</given-names>
</string-name>
,
<string-name>
<surname>Fleischmann</surname>
,
<given-names>W. R.</given-names>
</string-name>
,
<string-name>
<surname>Coppenhaver</surname>
,
<given-names>D. H.</given-names>
</string-name>
,
<string-name>
<surname>Niesel</surname>
,
<given-names>D. W.</given-names>
</string-name>
,
<string-name>
<surname>Klimpel</surname>
,
<given-names>G. R.</given-names>
</string-name>
, …
<string-name>
<surname>Hughes</surname>
,
<given-names>T. K.</given-names>
</string-name>
(
<year>1991</year>
).
<article-title>The interferons: Mechanisms of action and clinical applications</article-title>
.
<source xml:lang="en">JAMA</source>
,
<volume>266</volume>
(
<issue>10</issue>
),
<fpage>1375</fpage>
<lpage>1383</lpage>
.
<pub-id pub-id-type="doi">10.1001/jama.1991.03470100067035</pub-id>
<pub-id pub-id-type="pmid">1715409</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0008">
<mixed-citation publication-type="journal" id="jnr24333-cit-0008">
<string-name>
<surname>Benakis</surname>
,
<given-names>C.</given-names>
</string-name>
,
<string-name>
<surname>Garcia‐Bonilla</surname>
,
<given-names>L.</given-names>
</string-name>
,
<string-name>
<surname>Iadecola</surname>
,
<given-names>C.</given-names>
</string-name>
, &
<string-name>
<surname>Anrather</surname>
,
<given-names>J.</given-names>
</string-name>
(
<year>2015</year>
).
<article-title>The role of microglia and myeloid immune cells in acute cerebral ischemia</article-title>
.
<source xml:lang="en">Frontiers in Cellular Neuroscience</source>
,
<volume>8</volume>
,
<fpage>461</fpage>
<pub-id pub-id-type="doi">10.3389/fncel.2014.00461</pub-id>
<pub-id pub-id-type="pmid">25642168</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0009">
<mixed-citation publication-type="journal" id="jnr24333-cit-0009">
<string-name>
<surname>Booy</surname>
,
<given-names>S.</given-names>
</string-name>
,
<string-name>
<surname>Hofland</surname>
,
<given-names>L.</given-names>
</string-name>
, &
<string-name>
<surname>van Eijck</surname>
,
<given-names>C.</given-names>
</string-name>
(
<year>2015</year>
).
<article-title>Potentials of interferon therapy in the treatment of pancreatic cancer</article-title>
.
<source xml:lang="en">Journal of Interferon & Cytokine Research</source>
,
<volume>35</volume>
(
<issue>5</issue>
),
<fpage>327</fpage>
<lpage>339</lpage>
.
<pub-id pub-id-type="doi">10.1089/jir.2014.0157</pub-id>
<pub-id pub-id-type="pmid">25551196</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0010">
<mixed-citation publication-type="journal" id="jnr24333-cit-0010">
<string-name>
<surname>Borst</surname>
,
<given-names>K.</given-names>
</string-name>
,
<string-name>
<surname>Frenz</surname>
,
<given-names>T.</given-names>
</string-name>
,
<string-name>
<surname>Spanier</surname>
,
<given-names>J.</given-names>
</string-name>
,
<string-name>
<surname>Tegtmeyer</surname>
,
<given-names>P.‐K.</given-names>
</string-name>
,
<string-name>
<surname>Chhatbar</surname>
,
<given-names>C.</given-names>
</string-name>
,
<string-name>
<surname>Skerra</surname>
,
<given-names>J.</given-names>
</string-name>
, …
<string-name>
<surname>Köster</surname>
,
<given-names>M.</given-names>
</string-name>
(
<year>2018</year>
).
<article-title>Type I interferon receptor signaling delays Kupffer cell replenishment during acute fulminant viral hepatitis</article-title>
.
<source xml:lang="en">Journal of Hepatology</source>
,
<volume>68</volume>
(
<issue>4</issue>
),
<fpage>682</fpage>
<lpage>690</lpage>
.
<pub-id pub-id-type="doi">10.1016/j.jhep.2017.11.029</pub-id>
<pub-id pub-id-type="pmid">29274730</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0011">
<mixed-citation publication-type="journal" id="jnr24333-cit-0011">
<string-name>
<surname>Carroll</surname>
,
<given-names>W.</given-names>
</string-name>
(
<year>2009</year>
).
<article-title>Clinical trials of multiple sclerosis therapies: Improvements to demonstrate long‐term patient benefit</article-title>
.
<source xml:lang="en">Multiple Sclerosis Journal</source>
,
<volume>15</volume>
(
<issue>8</issue>
),
<fpage>951</fpage>
<lpage>958</lpage>
.
<pub-id pub-id-type="doi">10.1177/1352458509105426</pub-id>
<pub-id pub-id-type="pmid">19465446</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0012">
<mixed-citation publication-type="journal" id="jnr24333-cit-0012">
<string-name>
<surname>Chaturvedi</surname>
,
<given-names>M.</given-names>
</string-name>
, &
<string-name>
<surname>Kaczmarek</surname>
,
<given-names>L.</given-names>
</string-name>
(
<year>2014</year>
).
<article-title>Mmp‐9 inhibition: A therapeutic strategy in ischemic stroke</article-title>
.
<source xml:lang="en">Molecular Neurobiology</source>
,
<volume>49</volume>
(
<issue>1</issue>
),
<fpage>563</fpage>
<lpage>573</lpage>
.
<pub-id pub-id-type="doi">10.1007/s12035-013-8538-z</pub-id>
<pub-id pub-id-type="pmid">24026771</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0013">
<mixed-citation publication-type="journal" id="jnr24333-cit-0013">
<string-name>
<surname>Conigliaro</surname>
,
<given-names>P.</given-names>
</string-name>
,
<string-name>
<surname>Perricone</surname>
,
<given-names>C.</given-names>
</string-name>
,
<string-name>
<surname>Benson</surname>
,
<given-names>R. A.</given-names>
</string-name>
,
<string-name>
<surname>Garside</surname>
,
<given-names>P.</given-names>
</string-name>
,
<string-name>
<surname>Brewer</surname>
,
<given-names>J. M.</given-names>
</string-name>
,
<string-name>
<surname>Perricone</surname>
,
<given-names>R.</given-names>
</string-name>
, &
<string-name>
<surname>Valesini</surname>
,
<given-names>G.</given-names>
</string-name>
(
<year>2010</year>
).
<article-title>The type I IFN system in rheumatoid arthritis</article-title>
.
<source xml:lang="en">Autoimmunity</source>
,
<volume>43</volume>
(
<issue>3</issue>
),
<fpage>220</fpage>
<lpage>225</lpage>
.
<pub-id pub-id-type="doi">10.3109/08916930903510914</pub-id>
<pub-id pub-id-type="pmid">20166872</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0014">
<mixed-citation publication-type="journal" id="jnr24333-cit-0014">
<string-name>
<surname>Cruz</surname>
,
<given-names>S. A.</given-names>
</string-name>
,
<string-name>
<surname>Hari</surname>
,
<given-names>A.</given-names>
</string-name>
,
<string-name>
<surname>Qin</surname>
,
<given-names>Z.</given-names>
</string-name>
,
<string-name>
<surname>Couture</surname>
,
<given-names>P.</given-names>
</string-name>
,
<string-name>
<surname>Huang</surname>
,
<given-names>H.</given-names>
</string-name>
,
<string-name>
<surname>Lagace</surname>
,
<given-names>D. C.</given-names>
</string-name>
, …
<string-name>
<surname>Chen</surname>
,
<given-names>H.‐H.</given-names>
</string-name>
(
<year>2017</year>
).
<article-title>Loss of IRF2BP2 in microglia increases inflammation and functional deficits after focal ischemic brain injury</article-title>
.
<source xml:lang="en">Frontiers in Cellular Neuroscience</source>
,
<volume>11</volume>
,
<fpage>201</fpage>
<pub-id pub-id-type="doi">10.3389/fncel.2017.00201</pub-id>
<pub-id pub-id-type="pmid">28769762</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0015">
<mixed-citation publication-type="journal" id="jnr24333-cit-0015">
<string-name>
<surname>Dalakas</surname>
,
<given-names>M. C.</given-names>
</string-name>
(
<year>2008</year>
).
<article-title>B cells as therapeutic targets in autoimmune neurological disorders</article-title>
.
<source xml:lang="en">Nature Reviews Neurology</source>
,
<volume>4</volume>
(
<issue>10</issue>
),
<fpage>557</fpage>
<pub-id pub-id-type="doi">10.1038/ncpneuro0901</pub-id>
<pub-id pub-id-type="pmid">18813230</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0016">
<mixed-citation publication-type="journal" id="jnr24333-cit-0016">
<string-name>
<surname>Deb</surname>
,
<given-names>P.</given-names>
</string-name>
,
<string-name>
<surname>Sharma</surname>
,
<given-names>S.</given-names>
</string-name>
, &
<string-name>
<surname>Hassan</surname>
,
<given-names>K.</given-names>
</string-name>
(
<year>2010</year>
).
<article-title>Pathophysiologic mechanisms of acute ischemic stroke: An overview with emphasis on therapeutic significance beyond thrombolysis</article-title>
.
<source xml:lang="en">Pathophysiology</source>
,
<volume>17</volume>
(
<issue>3</issue>
),
<fpage>197</fpage>
<lpage>218</lpage>
.
<pub-id pub-id-type="doi">10.1016/j.pathophys.2009.12.001</pub-id>
<pub-id pub-id-type="pmid">20074922</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0017">
<mixed-citation publication-type="journal" id="jnr24333-cit-0017">
<string-name>
<surname>Denes</surname>
,
<given-names>A.</given-names>
</string-name>
,
<string-name>
<surname>Thornton</surname>
,
<given-names>P.</given-names>
</string-name>
,
<string-name>
<surname>Rothwell</surname>
,
<given-names>N.</given-names>
</string-name>
, &
<string-name>
<surname>Allan</surname>
,
<given-names>S.</given-names>
</string-name>
(
<year>2010</year>
).
<article-title>Inflammation and brain injury: Acute cerebral ischaemia, peripheral and central inflammation</article-title>
.
<source xml:lang="en">Brain, Behavior, and Immunity</source>
,
<volume>24</volume>
(
<issue>5</issue>
),
<fpage>708</fpage>
<lpage>723</lpage>
.
<pub-id pub-id-type="doi">10.1016/j.bbi.2009.09.010</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0018">
<mixed-citation publication-type="journal" id="jnr24333-cit-0018">
<string-name>
<surname>Dhib‐Jalbut</surname>
,
<given-names>S.</given-names>
</string-name>
, &
<string-name>
<surname>Marks</surname>
,
<given-names>S.</given-names>
</string-name>
(
<year>2010</year>
).
<article-title>Interferon‐β mechanisms of action in multiple sclerosis</article-title>
.
<source xml:lang="en">Neurology</source>
,
<volume>74</volume>
(
<issue>1 Suppl. 1</issue>
),
<fpage>S17</fpage>
<lpage>S24</lpage>
.
<ext-link ext-link-type="uri" xlink:href="https://doi:10.1212/WNL.0b013e3181c97d99">https://doi:10.1212/WNL.0b013e3181c97d99</ext-link>
<pub-id pub-id-type="pmid">20038758</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0019">
<mixed-citation publication-type="journal" id="jnr24333-cit-0019">
<string-name>
<surname>Dierckx</surname>
,
<given-names>T.</given-names>
</string-name>
,
<string-name>
<surname>Khouri</surname>
,
<given-names>R.</given-names>
</string-name>
,
<string-name>
<surname>Menezes</surname>
,
<given-names>S.</given-names>
</string-name>
,
<string-name>
<surname>Decanine</surname>
,
<given-names>D.</given-names>
</string-name>
,
<string-name>
<surname>Farre</surname>
,
<given-names>L.</given-names>
</string-name>
,
<string-name>
<surname>Bittencourt</surname>
,
<given-names>A.</given-names>
</string-name>
, …
<string-name>
<surname>Van Weyenbergh</surname>
,
<given-names>J.</given-names>
</string-name>
(
<year>2017</year>
).
<article-title>IFN‐β induces greater antiproliferative and proapoptotic effects and increased p53 signaling compared with IFN‐α in PBMCs of adult T‐cell Leukemia/Lymphoma patients</article-title>
.
<source xml:lang="en">Blood Cancer Journal</source>
,
<volume>7</volume>
(
<issue>1</issue>
),
<fpage>e519</fpage>
<pub-id pub-id-type="doi">10.1038/bcj.2016.126</pub-id>
<pub-id pub-id-type="pmid">28128792</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0020">
<mixed-citation publication-type="journal" id="jnr24333-cit-0020">
<string-name>
<surname>Dirnagl</surname>
,
<given-names>U.</given-names>
</string-name>
,
<string-name>
<surname>Iadecola</surname>
,
<given-names>C.</given-names>
</string-name>
, &
<string-name>
<surname>Moskowitz</surname>
,
<given-names>M. A.</given-names>
</string-name>
(
<year>1999</year>
).
<article-title>Pathobiology of ischaemic stroke: An integrated view</article-title>
.
<source xml:lang="en">Trends in Neurosciences</source>
,
<volume>22</volume>
(
<issue>9</issue>
),
<fpage>391</fpage>
<lpage>397</lpage>
.
<pub-id pub-id-type="doi">10.1016/S0166-2236(99)01401-0</pub-id>
<pub-id pub-id-type="pmid">10441299</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0021">
<mixed-citation publication-type="journal" id="jnr24333-cit-0021">
<string-name>
<surname>Fann</surname>
,
<given-names>D.‐Y.‐W.</given-names>
</string-name>
,
<string-name>
<surname>Lee</surname>
,
<given-names>S.‐Y.</given-names>
</string-name>
,
<string-name>
<surname>Manzanero</surname>
,
<given-names>S.</given-names>
</string-name>
,
<string-name>
<surname>Chunduri</surname>
,
<given-names>P.</given-names>
</string-name>
,
<string-name>
<surname>Sobey</surname>
,
<given-names>C. G.</given-names>
</string-name>
, &
<string-name>
<surname>Arumugam</surname>
,
<given-names>T. V.</given-names>
</string-name>
(
<year>2013</year>
).
<article-title>Pathogenesis of acute stroke and the role of inflammasomes</article-title>
.
<source xml:lang="en">Ageing Research Reviews</source>
,
<volume>12</volume>
(
<issue>4</issue>
),
<fpage>941</fpage>
<lpage>966</lpage>
.
<pub-id pub-id-type="doi">10.1016/j.arr.2013.09.004</pub-id>
<pub-id pub-id-type="pmid">24103368</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0022">
<mixed-citation publication-type="journal" id="jnr24333-cit-0022">
<string-name>
<surname>Fragoso</surname>
,
<given-names>Y. D.</given-names>
</string-name>
,
<string-name>
<surname>Frota</surname>
,
<given-names>E. R. C.</given-names>
</string-name>
,
<string-name>
<surname>Lopes</surname>
,
<given-names>J. S.</given-names>
</string-name>
,
<string-name>
<surname>Noal</surname>
,
<given-names>J. S.</given-names>
</string-name>
,
<string-name>
<surname>Giacomo</surname>
,
<given-names>M. C.</given-names>
</string-name>
,
<string-name>
<surname>Gomes</surname>
,
<given-names>S.</given-names>
</string-name>
, …
<string-name>
<surname>Finkelsztejn</surname>
,
<given-names>A.</given-names>
</string-name>
(
<year>2010</year>
).
<article-title>Severe depression, suicide attempts, and ideation during the use of interferon beta by patients with multiple sclerosis</article-title>
.
<source xml:lang="en">Clinical Neuropharmacology</source>
,
<volume>33</volume>
(
<issue>6</issue>
),
<fpage>312</fpage>
<lpage>316</lpage>
.
<pub-id pub-id-type="doi">10.1097/WNF.0b013e3181f8d513</pub-id>
<pub-id pub-id-type="pmid">21079457</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0023">
<mixed-citation publication-type="journal" id="jnr24333-cit-0023">
<string-name>
<surname>Franscina Pinto</surname>
,
<given-names>E.</given-names>
</string-name>
, &
<string-name>
<surname>Andrade</surname>
,
<given-names>C.</given-names>
</string-name>
(
<year>2016</year>
).
<article-title>Interferon‐related depression: A primer on mechanisms, treatment, and prevention of a common clinical problem</article-title>
.
<source xml:lang="en">Current Neuropharmacology</source>
,
<volume>14</volume>
(
<issue>7</issue>
),
<fpage>743</fpage>
<lpage>748</lpage>
.
<pub-id pub-id-type="doi">10.2174/1570159X14666160106155129</pub-id>
<pub-id pub-id-type="pmid">26733280</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0024">
<mixed-citation publication-type="journal" id="jnr24333-cit-0024">
<string-name>
<surname>Friedman</surname>
,
<given-names>R. M.</given-names>
</string-name>
(
<year>2008</year>
).
<article-title>Clinical uses of interferons</article-title>
.
<source xml:lang="en">British Journal of Clinical Pharmacology</source>
,
<volume>65</volume>
(
<issue>2</issue>
),
<fpage>158</fpage>
<lpage>162</lpage>
.
<pub-id pub-id-type="doi">10.1111/j.1365-2125.2007.03055.x</pub-id>
<pub-id pub-id-type="pmid">18070219</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0025">
<mixed-citation publication-type="journal" id="jnr24333-cit-0025">
<string-name>
<surname>Fritsch</surname>
,
<given-names>S. D.</given-names>
</string-name>
, &
<string-name>
<surname>Weichhart</surname>
,
<given-names>T.</given-names>
</string-name>
(
<year>2016</year>
).
<article-title>Effects of interferons and viruses on metabolism</article-title>
.
<source xml:lang="en">Frontiers in Immunology</source>
,
<volume>7</volume>
,
<fpage>630</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2016.00630</pub-id>
<pub-id pub-id-type="pmid">28066439</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0026">
<mixed-citation publication-type="miscellaneous" id="jnr24333-cit-0026">
<string-name>
<surname>Gao</surname>
,
<given-names>L</given-names>
</string-name>
.,
<string-name>
<surname>Anolik</surname>
,
<given-names>J</given-names>
</string-name>
., &
<string-name>
<surname>Looney</surname>
,
<given-names>R</given-names>
</string-name>
. (
<year>2018</year>
). PS7: 130 Interferon beta blockade rescues human bm‐msc osteoblastogenesis defects in systemic lupus erythematosus: Archives of disease in childhood.
<pub-id pub-id-type="doi">10.1136/lupus-2018-abstract.173</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0027">
<mixed-citation publication-type="journal" id="jnr24333-cit-0027">
<string-name>
<surname>Gelderblom</surname>
,
<given-names>M.</given-names>
</string-name>
,
<string-name>
<surname>Arunachalam</surname>
,
<given-names>P.</given-names>
</string-name>
, &
<string-name>
<surname>Magnus</surname>
,
<given-names>T.</given-names>
</string-name>
<year>(2014)</year>
<article-title>γδ T cells as early sensors of tissue damage and mediators of secondary neurodegeneration</article-title>
.
<source xml:lang="en">Frontiers in Cellular Neuroscience</source>
,
<volume>8</volume>
(
<issue>1–5</issue>
),
<fpage>368</fpage>
<pub-id pub-id-type="doi">10.1136/lupus-2018-abstract.173</pub-id>
<pub-id pub-id-type="pmid">25414640</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0028">
<mixed-citation publication-type="journal" id="jnr24333-cit-0028">
<string-name>
<surname>Genç</surname>
,
<given-names>K.</given-names>
</string-name>
,
<string-name>
<surname>Dona</surname>
,
<given-names>D. L.</given-names>
</string-name>
, &
<string-name>
<surname>Reder</surname>
,
<given-names>A. T</given-names>
</string-name>
. (
<year>1997</year>
).
<article-title>Increased CD80 (+) B cells in active multiple sclerosis and reversal by interferon beta‐1b therapy</article-title>
.
<source xml:lang="en">The Journal of Clinical Investigation</source>
,
<volume>99</volume>
(
<issue>11</issue>
),
<fpage>2664</fpage>
<lpage>2671</lpage>
.
<pub-id pub-id-type="doi">10.1172/JCI119455</pub-id>
<pub-id pub-id-type="pmid">9169496</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0029">
<mixed-citation publication-type="journal" id="jnr24333-cit-0029">
<string-name>
<surname>George</surname>
,
<given-names>P. M.</given-names>
</string-name>
, &
<string-name>
<surname>Steinberg</surname>
,
<given-names>G. K.</given-names>
</string-name>
(
<year>2015</year>
).
<article-title>Novel stroke therapeutics: Unraveling stroke pathophysiology and its impact on clinical treatments</article-title>
.
<source xml:lang="en">Neuron</source>
,
<volume>87</volume>
(
<issue>2</issue>
),
<fpage>297</fpage>
<lpage>309</lpage>
.
<pub-id pub-id-type="doi">10.1016/j.neuron.2015.05.041</pub-id>
<pub-id pub-id-type="pmid">26182415</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0030">
<mixed-citation publication-type="journal" id="jnr24333-cit-0030">
<string-name>
<surname>Gesuete</surname>
,
<given-names>R.</given-names>
</string-name>
,
<string-name>
<surname>Packard</surname>
,
<given-names>A. E.</given-names>
</string-name>
,
<string-name>
<surname>Vartanian</surname>
,
<given-names>K. B.</given-names>
</string-name>
,
<string-name>
<surname>Conrad</surname>
,
<given-names>V. K.</given-names>
</string-name>
,
<string-name>
<surname>Stevens</surname>
,
<given-names>S. L.</given-names>
</string-name>
,
<string-name>
<surname>Bahjat</surname>
,
<given-names>F. R.</given-names>
</string-name>
, …
<string-name>
<surname>Stenzel‐Poore</surname>
,
<given-names>M. P.</given-names>
</string-name>
(
<year>2012</year>
).
<article-title>Poly‐ICLC preconditioning protects the blood–brain barrier against ischemic injury in vitro through type I interferon signaling</article-title>
.
<source xml:lang="en">Journal of Neurochemistry</source>
,
<volume>123</volume>
,
<fpage>75</fpage>
<lpage>85</lpage>
.
<ext-link ext-link-type="uri" xlink:href="https://doi:10.1111/j.1471-4159.2012.07946.x.">https://doi:10.1111/j.1471-4159.2012.07946.x.</ext-link>
<pub-id pub-id-type="pmid">23050645</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0031">
<mixed-citation publication-type="journal" id="jnr24333-cit-0031">
<string-name>
<surname>Gonzales‐van Horn</surname>
,
<given-names>S. R.</given-names>
</string-name>
, &
<string-name>
<surname>Farrar</surname>
,
<given-names>J. D.</given-names>
</string-name>
(
<year>2015</year>
).
<article-title>Interferon at the crossroads of allergy and viral infections</article-title>
.
<source xml:lang="en">Journal of Leukocyte Biology</source>
,
<volume>98</volume>
(
<issue>2</issue>
),
<fpage>185</fpage>
<lpage>194</lpage>
.
<pub-id pub-id-type="doi">10.1189/jlb.3RU0315-099R</pub-id>
<pub-id pub-id-type="pmid">26026068</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0032">
<mixed-citation publication-type="journal" id="jnr24333-cit-0032">
<string-name>
<surname>Hamner</surname>
,
<given-names>M. A.</given-names>
</string-name>
,
<string-name>
<surname>Ye</surname>
,
<given-names>Z.</given-names>
</string-name>
,
<string-name>
<surname>Lee</surname>
,
<given-names>R. V.</given-names>
</string-name>
,
<string-name>
<surname>Colman</surname>
,
<given-names>J. R.</given-names>
</string-name>
,
<string-name>
<surname>Le</surname>
,
<given-names>T.</given-names>
</string-name>
,
<string-name>
<surname>Gong</surname>
,
<given-names>D. C.</given-names>
</string-name>
, …
<string-name>
<surname>Weinstein</surname>
,
<given-names>J. R.</given-names>
</string-name>
(
<year>2015</year>
).
<article-title>Ischemic preconditioning in white matter: Magnitude and mechanism</article-title>
.
<source xml:lang="en">Journal of Neuroscience</source>
,
<volume>35</volume>
(
<issue>47</issue>
),
<fpage>15599</fpage>
<lpage>15611</lpage>
.
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.2544-15.2015</pub-id>
<pub-id pub-id-type="pmid">26609155</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0033">
<mixed-citation publication-type="journal" id="jnr24333-cit-0033">
<string-name>
<surname>Hansen</surname>
,
<given-names>M. V.</given-names>
</string-name>
,
<string-name>
<surname>Danielsen</surname>
,
<given-names>A. K.</given-names>
</string-name>
,
<string-name>
<surname>Hageman</surname>
,
<given-names>I.</given-names>
</string-name>
,
<string-name>
<surname>Rosenberg</surname>
,
<given-names>J.</given-names>
</string-name>
, &
<string-name>
<surname>Gögenur</surname>
,
<given-names>I.</given-names>
</string-name>
(
<year>2014</year>
).
<article-title>The therapeutic or prophylactic effect of exogenous melatonin against depression and depressive symptoms: A systematic review and meta‐analysis</article-title>
.
<source xml:lang="en">European Neuropsychopharmacology</source>
,
<volume>24</volume>
(
<issue>11</issue>
),
<fpage>1719</fpage>
<lpage>1728</lpage>
.
<pub-id pub-id-type="doi">10.1016/j.euroneuro.2014.08.008</pub-id>
<pub-id pub-id-type="pmid">25224106</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0034">
<mixed-citation publication-type="journal" id="jnr24333-cit-0034">
<string-name>
<surname>Hori</surname>
,
<given-names>M.</given-names>
</string-name>
,
<string-name>
<surname>Nakamachi</surname>
,
<given-names>T.</given-names>
</string-name>
,
<string-name>
<surname>Rakwal</surname>
,
<given-names>R.</given-names>
</string-name>
,
<string-name>
<surname>Shibato</surname>
,
<given-names>J.</given-names>
</string-name>
,
<string-name>
<surname>Nakamura</surname>
,
<given-names>K.</given-names>
</string-name>
,
<string-name>
<surname>Wada</surname>
,
<given-names>Y.</given-names>
</string-name>
, …
<string-name>
<surname>Shioda</surname>
,
<given-names>S.</given-names>
</string-name>
(
<year>2012</year>
).
<article-title>Unraveling the ischemic brain transcriptome in a permanent middle cerebral artery occlusion mouse model by DNA microarray analysis</article-title>
.
<source xml:lang="en">Disease Models & Mechanisms</source>
,
<volume>5</volume>
(
<issue>2</issue>
),
<fpage>270</fpage>
<lpage>283</lpage>
.
<pub-id pub-id-type="doi">10.1242/dmm.008276</pub-id>
<pub-id pub-id-type="pmid">22015461</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0035">
<mixed-citation publication-type="journal" id="jnr24333-cit-0035">
<string-name>
<surname>Huang</surname>
,
<given-names>H</given-names>
</string-name>
.,
<string-name>
<surname>Ito</surname>
,
<given-names>K</given-names>
</string-name>
.,
<string-name>
<surname>Dangond</surname>
,
<given-names>F</given-names>
</string-name>
., &
<string-name>
<surname>Dhib‐Jalbut</surname>
,
<given-names>S</given-names>
</string-name>
. (
<year>2013</year>
).
<article-title>Effect of interferon beta‐1a on B7.1 and B7.2 B‐cell expression and its impact on T‐cell proliferation</article-title>
.
<source xml:lang="en">Journal of Neuroimmunology</source>
,
<volume>258</volume>
(
<issue>1</issue>
),
<fpage>27</fpage>
<lpage>31</lpage>
.
<pub-id pub-id-type="doi">10.1016/j.jneuroim.2013.02.010</pub-id>
<pub-id pub-id-type="pmid">23489746</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0036">
<mixed-citation publication-type="journal" id="jnr24333-cit-0036">
<string-name>
<surname>Imanishi</surname>
,
<given-names>J.</given-names>
</string-name>
(
<year>1994</year>
).
<article-title>Interferon‐alpha, beta, gamma. </article-title>
<source xml:lang="en">Gan to kagaku ryoho. Cancer & Chemotherapy</source>
,
<volume>21</volume>
(
<issue>16</issue>
),
<fpage>2853</fpage>
<lpage>2858</lpage>
.
<pub-id pub-id-type="pmid">7993128</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0037">
<mixed-citation publication-type="journal" id="jnr24333-cit-0037">
<string-name>
<surname>Inácio</surname>
,
<given-names>A. R.</given-names>
</string-name>
,
<string-name>
<surname>Liu</surname>
,
<given-names>Y.</given-names>
</string-name>
,
<string-name>
<surname>Clausen</surname>
,
<given-names>B. H.</given-names>
</string-name>
,
<string-name>
<surname>Svensson</surname>
,
<given-names>M.</given-names>
</string-name>
,
<string-name>
<surname>Kucharz</surname>
,
<given-names>K.</given-names>
</string-name>
,
<string-name>
<surname>Yang</surname>
,
<given-names>Y.</given-names>
</string-name>
, …
<string-name>
<surname>Issazadeh‐Navikas</surname>
,
<given-names>S.</given-names>
</string-name>
(
<year>2015</year>
).
<article-title>Endogenous IFN‐β signaling exerts anti‐inflammatory actions in experimentally induced focal cerebral ischemia</article-title>
.
<source xml:lang="en">Journal of Neuroinflammation</source>
,
<volume>12</volume>
(
<issue>1</issue>
),
<fpage>211</fpage>
<pub-id pub-id-type="doi">10.1186/s12974-015-0427-0</pub-id>
<pub-id pub-id-type="pmid">26581581</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0038">
<mixed-citation publication-type="journal" id="jnr24333-cit-0038">
<string-name>
<surname>Jaeckel</surname>
,
<given-names>E.</given-names>
</string-name>
,
<string-name>
<surname>Cornberg</surname>
,
<given-names>M.</given-names>
</string-name>
,
<string-name>
<surname>Wedemeyer</surname>
,
<given-names>H.</given-names>
</string-name>
,
<string-name>
<surname>Santantonio</surname>
,
<given-names>T.</given-names>
</string-name>
,
<string-name>
<surname>Mayer</surname>
,
<given-names>J.</given-names>
</string-name>
,
<string-name>
<surname>Zankel</surname>
,
<given-names>M.</given-names>
</string-name>
, …
<string-name>
<surname>Manns</surname>
,
<given-names>M. P.</given-names>
</string-name>
(
<year>2001</year>
).
<article-title>Treatment of acute hepatitis C with interferon alfa‐2b</article-title>
.
<source xml:lang="en">New England Journal of Medicine</source>
,
<volume>345</volume>
(
<issue>20</issue>
),
<fpage>1452</fpage>
<lpage>1457</lpage>
.
<pub-id pub-id-type="doi">10.1056/NEJMoa011232</pub-id>
<pub-id pub-id-type="pmid">11794193</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0039">
<mixed-citation publication-type="journal" id="jnr24333-cit-0039">
<string-name>
<surname>Jiang</surname>
,
<given-names>H.</given-names>
</string-name>
,
<string-name>
<surname>Milo</surname>
,
<given-names>R.</given-names>
</string-name>
,
<string-name>
<surname>Swoveland</surname>
,
<given-names>P.</given-names>
</string-name>
,
<string-name>
<surname>Johnson</surname>
,
<given-names>K. P.</given-names>
</string-name>
,
<string-name>
<surname>Panitch</surname>
,
<given-names>H.</given-names>
</string-name>
, &
<string-name>
<surname>Dhib‐Jalbut</surname>
,
<given-names>S.</given-names>
</string-name>
(
<year>1995</year>
).
<article-title>Interferon β‐lb reduces Interferon γ‐induced antigen‐presenting capacity of human glial and B cells</article-title>
.
<source xml:lang="en">Journal of Neuroimmunology</source>
,
<volume>61</volume>
(
<issue>1</issue>
),
<fpage>17</fpage>
<lpage>25</lpage>
.
<pub-id pub-id-type="doi">10.1016/0165-5728(95)00072-A</pub-id>
<pub-id pub-id-type="pmid">7560008</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0040">
<mixed-citation publication-type="journal" id="jnr24333-cit-0040">
<string-name>
<surname>Jin</surname>
,
<given-names>R.</given-names>
</string-name>
,
<string-name>
<surname>Yang</surname>
,
<given-names>G.</given-names>
</string-name>
, &
<string-name>
<surname>Li</surname>
,
<given-names>G.</given-names>
</string-name>
(
<year>2010</year>
).
<article-title>Inflammatory mechanisms in ischemic stroke: Role of inflammatory cells</article-title>
.
<source xml:lang="en">Journal of Leukocyte Biology</source>
,
<volume>87</volume>
(
<issue>5</issue>
),
<fpage>779</fpage>
<lpage>789</lpage>
.
<pub-id pub-id-type="doi">10.1189/jlb.1109766</pub-id>
<pub-id pub-id-type="pmid">20130219</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0041">
<mixed-citation publication-type="journal" id="jnr24333-cit-0041">
<string-name>
<surname>Kasper</surname>
,
<given-names>L. H.</given-names>
</string-name>
, &
<string-name>
<surname>Reder</surname>
,
<given-names>A. T.</given-names>
</string-name>
(
<year>2014</year>
).
<article-title>Immunomodulatory activity of interferon‐beta</article-title>
.
<source xml:lang="en">Annals of Clinical and Translational Neurology</source>
,
<volume>1</volume>
(
<issue>8</issue>
),
<fpage>622</fpage>
<lpage>631</lpage>
.
<pub-id pub-id-type="doi">10.1002/acn3.84</pub-id>
<pub-id pub-id-type="pmid">25356432</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0042">
<mixed-citation publication-type="journal" id="jnr24333-cit-0042">
<string-name>
<surname>Kaur</surname>
,
<given-names>H.</given-names>
</string-name>
,
<string-name>
<surname>Sarmah</surname>
,
<given-names>D.</given-names>
</string-name>
,
<string-name>
<surname>Saraf</surname>
,
<given-names>J.</given-names>
</string-name>
,
<string-name>
<surname>Vats</surname>
,
<given-names>K.</given-names>
</string-name>
,
<string-name>
<surname>Kalia</surname>
,
<given-names>K.</given-names>
</string-name>
, &
<string-name>
<surname>Borah</surname>
,
<given-names>A.</given-names>
</string-name>
, …
<string-name>
<surname>Bhattacharya</surname>
,
<given-names>P</given-names>
</string-name>
. (
<year>2018</year>
).
<article-title>Noncoding RNAs in ischemic stroke: Time to translate</article-title>
.
<source xml:lang="en">Annals of the New York Academy of Sciences</source>
,
<volume>1421</volume>
(
<issue>1</issue>
),
<fpage>19</fpage>
<lpage>36</lpage>
.
<pub-id pub-id-type="doi">10.1111/nyas.13612</pub-id>
<pub-id pub-id-type="pmid">29683506</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0043">
<mixed-citation publication-type="journal" id="jnr24333-cit-0043">
<string-name>
<surname>Kawabori</surname>
,
<given-names>M.</given-names>
</string-name>
,
<string-name>
<surname>Yenari</surname>
,
<given-names>A.</given-names>
</string-name>
, &
<string-name>
<surname>M.</surname>
</string-name>
(
<year>2015</year>
).
<article-title>Inflammatory responses in brain ischemia</article-title>
.
<source xml:lang="en">Current Medicinal Chemistry</source>
,
<volume>22</volume>
(
<issue>10</issue>
),
<fpage>1258</fpage>
<lpage>1277</lpage>
.
<ext-link ext-link-type="uri" xlink:href="https://doi.10.2174/0929867322666150209154036">https://doi.10.2174/0929867322666150209154036</ext-link>
<pub-id pub-id-type="pmid">25666795</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0044">
<mixed-citation publication-type="journal" id="jnr24333-cit-0044">
<string-name>
<surname>Kieseier</surname>
,
<given-names>B. C.</given-names>
</string-name>
(
<year>2011</year>
).
<article-title>The mechanism of action of interferon‐β in relapsing multiple sclerosis</article-title>
.
<source xml:lang="en">CNS Drugs</source>
,
<volume>25</volume>
(
<issue>6</issue>
),
<fpage>491</fpage>
<lpage>502</lpage>
.
<pub-id pub-id-type="doi">10.2165/11591110-000000000-00000</pub-id>
<pub-id pub-id-type="pmid">21649449</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0045">
<mixed-citation publication-type="journal" id="jnr24333-cit-0045">
<string-name>
<surname>Kolb‐Mäurer</surname>
,
<given-names>A.</given-names>
</string-name>
,
<string-name>
<surname>Goebeler</surname>
,
<given-names>M.</given-names>
</string-name>
, &
<string-name>
<surname>Mäurer</surname>
,
<given-names>M.</given-names>
</string-name>
(
<year>2015</year>
).
<article-title>Cutaneous adverse events associated with interferon‐β treatment of multiple sclerosis</article-title>
.
<source xml:lang="en">International Journal of Molecular Sciences</source>
,
<volume>16</volume>
(
<issue>7</issue>
),
<fpage>14951</fpage>
<lpage>14960</lpage>
.
<pub-id pub-id-type="doi">10.3390/ijms160714951</pub-id>
<pub-id pub-id-type="pmid">26147425</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0046">
<mixed-citation publication-type="journal" id="jnr24333-cit-0046">
<string-name>
<surname>Kopitar‐Jerala</surname>
,
<given-names>N.</given-names>
</string-name>
(
<year>2017</year>
).
<article-title>The role of interferons in inflammation and inflammasome activation</article-title>
.
<source xml:lang="en">Frontiers in Immunology</source>
,
<volume>8</volume>
,
<fpage>873</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2017.00873</pub-id>
<pub-id pub-id-type="pmid">28791024</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0047">
<mixed-citation publication-type="journal" id="jnr24333-cit-0047">
<string-name>
<surname>Kotredes</surname>
,
<given-names>K. P.</given-names>
</string-name>
,
<string-name>
<surname>Thomas</surname>
,
<given-names>B.</given-names>
</string-name>
, &
<string-name>
<surname>Gamero</surname>
,
<given-names>A. M.</given-names>
</string-name>
(
<year>2017</year>
).
<article-title>The protective role of type I interferons in the gastrointestinal tract</article-title>
.
<source xml:lang="en">Frontiers in Immunology</source>
,
<volume>8</volume>
,
<fpage>410</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2017.00410</pub-id>
<pub-id pub-id-type="pmid">28428788</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0048">
<mixed-citation publication-type="journal" id="jnr24333-cit-0048">
<string-name>
<surname>Kraus</surname>
,
<given-names>J.</given-names>
</string-name>
, &
<string-name>
<surname>Oschmann</surname>
,
<given-names>P.</given-names>
</string-name>
(
<year>2006</year>
).
<article-title>The impact of interferon‐β treatment on the blood–brain barrier</article-title>
.
<source xml:lang="en">Drug Discovery Today</source>
,
<volume>11</volume>
(
<issue>15–16</issue>
),
<fpage>755</fpage>
<lpage>762</lpage>
.
<pub-id pub-id-type="doi">10.1016/j.drudis.2006.06.008</pub-id>
<pub-id pub-id-type="pmid">16846804</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0049">
<mixed-citation publication-type="journal" id="jnr24333-cit-0049">
<string-name>
<surname>Krumbholz</surname>
,
<given-names>M.</given-names>
</string-name>
,
<string-name>
<surname>Faber</surname>
,
<given-names>H.</given-names>
</string-name>
,
<string-name>
<surname>Steinmeyer</surname>
,
<given-names>F.</given-names>
</string-name>
,
<string-name>
<surname>Hoffmann</surname>
,
<given-names>L.‐A.</given-names>
</string-name>
,
<string-name>
<surname>Kümpfel</surname>
,
<given-names>T.</given-names>
</string-name>
,
<string-name>
<surname>Pellkofer</surname>
,
<given-names>H.</given-names>
</string-name>
, …
<string-name>
<surname>Hafner</surname>
,
<given-names>C.</given-names>
</string-name>
(
<year>2008</year>
).
<article-title>Interferon‐β increases BAFF levels in multiple sclerosis: Implications for B cell autoimmunity</article-title>
.
<source xml:lang="en">Brain</source>
,
<volume>131</volume>
(
<issue>6</issue>
),
<fpage>1455</fpage>
<lpage>1463</lpage>
.
<pub-id pub-id-type="doi">10.1093/brain/awn077</pub-id>
<pub-id pub-id-type="pmid">18474519</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0050">
<mixed-citation publication-type="journal" id="jnr24333-cit-0050">
<string-name>
<surname>Krumbholz</surname>
,
<given-names>M.</given-names>
</string-name>
,
<string-name>
<surname>Theil</surname>
,
<given-names>D.</given-names>
</string-name>
,
<string-name>
<surname>Derfuss</surname>
,
<given-names>T.</given-names>
</string-name>
,
<string-name>
<surname>Rosenwald</surname>
,
<given-names>A.</given-names>
</string-name>
,
<string-name>
<surname>Schrader</surname>
,
<given-names>F.</given-names>
</string-name>
,
<string-name>
<surname>Monoranu</surname>
,
<given-names>C.‐M.</given-names>
</string-name>
, …
<string-name>
<surname>Aloisi</surname>
,
<given-names>F.</given-names>
</string-name>
(
<year>2005</year>
).
<article-title>BAFF is produced by astrocytes and up‐regulated in multiple sclerosis lesions and primary central nervous system lymphoma</article-title>
.
<source xml:lang="en">Journal of Experimental Medicine</source>
,
<volume>201</volume>
(
<issue>2</issue>
),
<fpage>195</fpage>
<lpage>200</lpage>
.
<pub-id pub-id-type="doi">10.1084/jem.20041674</pub-id>
<pub-id pub-id-type="pmid">15642740</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0051">
<mixed-citation publication-type="journal" id="jnr24333-cit-0051">
<string-name>
<surname>Kuo</surname>
,
<given-names>P. C.</given-names>
</string-name>
,
<string-name>
<surname>Scofield</surname>
,
<given-names>B. A.</given-names>
</string-name>
,
<string-name>
<surname>Yu</surname>
,
<given-names>I. C.</given-names>
</string-name>
,
<string-name>
<surname>Chang</surname>
,
<given-names>F. L.</given-names>
</string-name>
,
<string-name>
<surname>Ganea</surname>
,
<given-names>D.</given-names>
</string-name>
, &
<string-name>
<surname>Yen</surname>
,
<given-names>J. H.</given-names>
</string-name>
(
<year>2016</year>
).
<article-title>Interferon‐β modulates inflammatory response in cerebral ischemia</article-title>
.
<source xml:lang="en">Journal of the American Heart Association</source>
,
<volume>5</volume>
(
<issue>1</issue>
),
<fpage>e002610</fpage>
<pub-id pub-id-type="doi">10.1161/JAHA.115.002610</pub-id>
<pub-id pub-id-type="pmid">26747000</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0052">
<mixed-citation publication-type="journal" id="jnr24333-cit-0052">
<string-name>
<surname>Lakhan</surname>
,
<given-names>S. E.</given-names>
</string-name>
,
<string-name>
<surname>Kirchgessner</surname>
,
<given-names>A.</given-names>
</string-name>
, &
<string-name>
<surname>Hofer</surname>
,
<given-names>M.</given-names>
</string-name>
(
<year>2009</year>
).
<article-title>Inflammatory mechanisms in ischemic stroke: Therapeutic approaches</article-title>
.
<source xml:lang="en">Journal of Translational Medicine</source>
,
<volume>7</volume>
(
<issue>1</issue>
),
<fpage>97</fpage>
<pub-id pub-id-type="doi">10.1186/1479-5876-7-97</pub-id>
<pub-id pub-id-type="pmid">19919699</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0053">
<mixed-citation publication-type="journal" id="jnr24333-cit-0053">
<string-name>
<surname>Le</surname>
,
<given-names>C. P.</given-names>
</string-name>
,
<string-name>
<surname>Genin</surname>
,
<given-names>P.</given-names>
</string-name>
,
<string-name>
<surname>Baines</surname>
,
<given-names>M.</given-names>
</string-name>
, &
<string-name>
<surname>Hiscott</surname>
,
<given-names>J.</given-names>
</string-name>
(
<year>2000</year>
).
<article-title>Interferon activation and innate immunity</article-title>
.
<source xml:lang="en">Reviews in Immunogenetics</source>
,
<volume>2</volume>
(
<issue>3</issue>
),
<fpage>374</fpage>
<lpage>386</lpage>
.
<pub-id pub-id-type="pmid">11256746</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0054">
<mixed-citation publication-type="journal" id="jnr24333-cit-0054">
<string-name>
<surname>Lindsberg</surname>
,
<given-names>P. J.</given-names>
</string-name>
,
<string-name>
<surname>Carpe</surname>
,
<given-names>O.</given-names>
</string-name>
,
<string-name>
<surname>Paetau</surname>
,
<given-names>A.</given-names>
</string-name>
,
<string-name>
<surname>Karjalainen‐Lindsberg</surname>
,
<given-names>M.‐L.</given-names>
</string-name>
, &
<string-name>
<surname>Kaste</surname>
,
<given-names>M.</given-names>
</string-name>
(
<year>1996</year>
).
<article-title>Endothelial ICAM‐1 expression associated with inflammatory cell response in human ischemic stroke</article-title>
.
<source xml:lang="en">Circulation</source>
,
<volume>94</volume>
(
<issue>5</issue>
),
<fpage>939</fpage>
<lpage>945</lpage>
.
<pub-id pub-id-type="doi">10.1161/01.CIR.94.5.939</pub-id>
<pub-id pub-id-type="pmid">8790029</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0055">
<mixed-citation publication-type="journal" id="jnr24333-cit-0055">
<string-name>
<surname>Maier</surname>
,
<given-names>C. M.</given-names>
</string-name>
,
<string-name>
<surname>Yu</surname>
,
<given-names>F.</given-names>
</string-name>
,
<string-name>
<surname>Nishi</surname>
,
<given-names>T.</given-names>
</string-name>
,
<string-name>
<surname>Lathrop</surname>
,
<given-names>S. J.</given-names>
</string-name>
, &
<string-name>
<surname>Chan</surname>
,
<given-names>P. H.</given-names>
</string-name>
(
<year>2006</year>
).
<article-title>Interferon‐β fails to protect in a model of transient focal stroke</article-title>
.
<source xml:lang="en">Stroke</source>
,
<volume>37</volume>
(
<issue>4</issue>
),
<fpage>1116</fpage>
<lpage>1119</lpage>
.
<ext-link ext-link-type="uri" xlink:href="https://doi:10.1161/01.STR.0000208214.46093.d5">https://doi:10.1161/01.STR.0000208214.46093.d5</ext-link>
<pub-id pub-id-type="pmid">16514094</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0056">
<mixed-citation publication-type="journal" id="jnr24333-cit-0056">
<string-name>
<surname>Markowitz</surname>
,
<given-names>C. E.</given-names>
</string-name>
(
<year>2007</year>
).
<article-title>Interferon‐beta mechanism of action and dosing issues</article-title>
.
<source xml:lang="en">Neurology</source>
,
<volume>68</volume>
(
<issue>24 Suppl. 4</issue>
),
<fpage>S8</fpage>
<lpage>S11</lpage>
.
<pub-id pub-id-type="doi">10.1212/01.wnl.0000277703.74115.d2</pub-id>
<pub-id pub-id-type="pmid">17562848</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0057">
<mixed-citation publication-type="journal" id="jnr24333-cit-0057">
<string-name>
<surname>McDonough</surname>
,
<given-names>A</given-names>
</string-name>
.,
<string-name>
<surname>Lee</surname>
,
<given-names>R. V</given-names>
</string-name>
.,
<string-name>
<surname>Noor</surname>
,
<given-names>S</given-names>
</string-name>
.,
<string-name>
<surname>Lee</surname>
,
<given-names>C</given-names>
</string-name>
.,
<string-name>
<surname>Le</surname>
,
<given-names>T</given-names>
</string-name>
.,
<string-name>
<surname>Iorga</surname>
,
<given-names>M</given-names>
</string-name>
., ...
<string-name>
<surname>Weinstein</surname>
,
<given-names>J. R</given-names>
</string-name>
. (
<year>2017</year>
).
<article-title>Ischemia/reperfusion induces interferon stimulated gene expression in microglia</article-title>
.
<source xml:lang="en">Journal of Neuroscience</source>
,
<volume>37,</volume>
<fpage>0725</fpage>
<lpage>0717</lpage>
.
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0725-17.2017</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0058">
<mixed-citation publication-type="journal" id="jnr24333-cit-0058">
<string-name>
<surname>McDonough</surname>
,
<given-names>A.</given-names>
</string-name>
, &
<string-name>
<surname>Weinstein</surname>
,
<given-names>J. R.</given-names>
</string-name>
(
<year>2016</year>
).
<article-title>Neuroimmune response in ischemic preconditioning</article-title>
.
<source xml:lang="en">Neurotherapeutics</source>
,
<volume>13</volume>
(
<issue>4</issue>
),
<fpage>748</fpage>
<lpage>761</lpage>
.
<pub-id pub-id-type="doi">10.1007/s13311-016-0465-z</pub-id>
<pub-id pub-id-type="pmid">27525700</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0059">
<mixed-citation publication-type="journal" id="jnr24333-cit-0059">
<string-name>
<surname>Meinl</surname>
,
<given-names>E.</given-names>
</string-name>
,
<string-name>
<surname>Krumbholz</surname>
,
<given-names>M.</given-names>
</string-name>
, &
<string-name>
<surname>Hohlfeld</surname>
,
<given-names>R.</given-names>
</string-name>
(
<year>2006</year>
).
<article-title>B lineage cells in the inflammatory central nervous system environment: Migration, maintenance, local antibody production, and therapeutic modulation</article-title>
.
<source xml:lang="en">Annals of Neurology</source>
,
<volume>59</volume>
(
<issue>6</issue>
),
<fpage>880</fpage>
<lpage>892</lpage>
.
<pub-id pub-id-type="doi">10.1002/ana.20890</pub-id>
<pub-id pub-id-type="pmid">16718690</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0060">
<mixed-citation publication-type="journal" id="jnr24333-cit-0060">
<string-name>
<surname>Minami</surname>
,
<given-names>M.</given-names>
</string-name>
,
<string-name>
<surname>Katayama</surname>
,
<given-names>T.</given-names>
</string-name>
, &
<string-name>
<surname>Satoh</surname>
,
<given-names>M.</given-names>
</string-name>
(
<year>2006</year>
).
<article-title>Brain cytokines and chemokines: Roles in ischemic injury and pain</article-title>
.
<source xml:lang="en">Journal of Pharmacological Sciences</source>
,
<volume>100</volume>
(
<issue>5</issue>
),
<fpage>461</fpage>
<lpage>470</lpage>
.
<pub-id pub-id-type="doi">10.1254/jphs.CRJ06005X</pub-id>
<pub-id pub-id-type="pmid">16682788</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0061">
<mixed-citation publication-type="book" id="jnr24333-cit-0061">
<string-name>
<surname>Moss</surname>
,
<given-names>J. W.</given-names>
</string-name>
, &
<string-name>
<surname>Ramji</surname>
,
<given-names>D. P.</given-names>
</string-name>
(
<year>2017</year>
).
<chapter-title>Cytokines in atherosclerosis</chapter-title>
<source xml:lang="en">Cytokine effector functions in tissues</source>
(pp.
<fpage>109</fpage>
<lpage>118</lpage>
).
<publisher-loc>United Kingdom</publisher-loc>
:
<publisher-name>Elsevier</publisher-name>
<pub-id pub-id-type="doi">10.1016/B978-0-12-804214-4.00005-1</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0062">
<mixed-citation publication-type="journal" id="jnr24333-cit-0062">
<string-name>
<surname>Nallar</surname>
,
<given-names>S. C.</given-names>
</string-name>
, &
<string-name>
<surname>Kalvakolanu</surname>
,
<given-names>D. V.</given-names>
</string-name>
(
<year>2014</year>
).
<article-title>Interferons, signal transduction pathways, and the central nervous system</article-title>
.
<source xml:lang="en">Journal of Interferon & Cytokine Research</source>
,
<volume>34</volume>
(
<issue>8</issue>
),
<fpage>559</fpage>
<lpage>576</lpage>
.
<pub-id pub-id-type="doi">10.1089/jir.2014.0021</pub-id>
<pub-id pub-id-type="pmid">25084173</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0063">
<mixed-citation publication-type="journal" id="jnr24333-cit-0063">
<string-name>
<surname>Perera</surname>
,
<given-names>M. N.</given-names>
</string-name>
,
<string-name>
<surname>Ma</surname>
,
<given-names>H. K.</given-names>
</string-name>
,
<string-name>
<surname>Arakawa</surname>
,
<given-names>S.</given-names>
</string-name>
,
<string-name>
<surname>Howells</surname>
,
<given-names>D. W.</given-names>
</string-name>
,
<string-name>
<surname>Markus</surname>
,
<given-names>R.</given-names>
</string-name>
,
<string-name>
<surname>Rowe</surname>
,
<given-names>C. C.</given-names>
</string-name>
, &
<string-name>
<surname>Donnan</surname>
,
<given-names>G. A.</given-names>
</string-name>
(
<year>2006</year>
).
<article-title>Inflammation following stroke</article-title>
.
<source xml:lang="en">Journal of Clinical Neuroscience</source>
,
<volume>13</volume>
(
<issue>1</issue>
),
<fpage>1</fpage>
<lpage>8</lpage>
.
<pub-id pub-id-type="doi">10.1016/j.jocn.2005.07.005</pub-id>
<pub-id pub-id-type="pmid">16410192</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0064">
<mixed-citation publication-type="journal" id="jnr24333-cit-0064">
<string-name>
<surname>Pestka</surname>
,
<given-names>S.</given-names>
</string-name>
(
<year>2007</year>
).
<article-title>The interferons: 50 years after their discovery, there is much more to learn</article-title>
.
<source xml:lang="en">Journal of Biological Chemistry</source>
,
<volume>282</volume>
(
<issue>28</issue>
),
<fpage>20047</fpage>
<lpage>20051</lpage>
.
<pub-id pub-id-type="doi">10.1074/jbc.R700004200</pub-id>
<pub-id pub-id-type="pmid">17502369</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0065">
<mixed-citation publication-type="journal" id="jnr24333-cit-0065">
<string-name>
<surname>Qaisar</surname>
,
<given-names>N.</given-names>
</string-name>
,
<string-name>
<surname>Jurczyk</surname>
,
<given-names>A.</given-names>
</string-name>
, &
<string-name>
<surname>Wang</surname>
,
<given-names>J. P.</given-names>
</string-name>
(
<year>2018</year>
).
<article-title>Potential role of type I interferon in the pathogenic process leading to type 1 diabetes</article-title>
.
<source xml:lang="en">Current Opinion in Endocrinology, Diabetes and Obesity</source>
,
<volume>25</volume>
(
<issue>2</issue>
),
<fpage>94</fpage>
<lpage>100</lpage>
.
<pub-id pub-id-type="doi">10.1097/MED.0000000000000399</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0066">
<mixed-citation publication-type="journal" id="jnr24333-cit-0066">
<string-name>
<surname>Rudick</surname>
,
<given-names>R. A.</given-names>
</string-name>
, &
<string-name>
<surname>Goelz</surname>
,
<given-names>S. E.</given-names>
</string-name>
(
<year>2011</year>
).
<article-title>Beta‐interferon for multiple sclerosis</article-title>
.
<source xml:lang="en">Experimental Cell Research</source>
,
<volume>317</volume>
(
<issue>9</issue>
),
<fpage>1301</fpage>
<lpage>1311</lpage>
.
<pub-id pub-id-type="doi">10.1016/j.yexcr.2011.03.002</pub-id>
<pub-id pub-id-type="pmid">21396360</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0067">
<mixed-citation publication-type="journal" id="jnr24333-cit-0067">
<string-name>
<surname>Samuel</surname>
,
<given-names>C. E.</given-names>
</string-name>
(
<year>2001</year>
).
<article-title>Antiviral actions of interferons</article-title>
.
<source xml:lang="en">Clinical Microbiology Reviews</source>
,
<volume>14</volume>
(
<issue>4</issue>
),
<fpage>778</fpage>
<lpage>809</lpage>
.
<pub-id pub-id-type="doi">10.1128/CMR.14.4.778-809.2001</pub-id>
<pub-id pub-id-type="pmid">11585785</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0068">
<mixed-citation publication-type="journal" id="jnr24333-cit-0068">
<string-name>
<surname>Schreiber</surname>
,
<given-names>G.</given-names>
</string-name>
, &
<string-name>
<surname>Piehler</surname>
,
<given-names>J.</given-names>
</string-name>
(
<year>2015</year>
).
<article-title>The molecular basis for functional plasticity in type I interferon signaling</article-title>
.
<source xml:lang="en">Trends in Immunology</source>
,
<volume>36</volume>
(
<issue>3</issue>
),
<fpage>139</fpage>
<lpage>149</lpage>
.
<pub-id pub-id-type="doi">10.1016/j.it.2015.01.002</pub-id>
<pub-id pub-id-type="pmid">25687684</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0069">
<mixed-citation publication-type="journal" id="jnr24333-cit-0069">
<string-name>
<surname>Sheppard</surname>
,
<given-names>P.</given-names>
</string-name>
,
<string-name>
<surname>Kindsvogel</surname>
,
<given-names>W.</given-names>
</string-name>
,
<string-name>
<surname>Xu</surname>
,
<given-names>W.</given-names>
</string-name>
,
<string-name>
<surname>Henderson</surname>
,
<given-names>K.</given-names>
</string-name>
,
<string-name>
<surname>Schlutsmeyer</surname>
,
<given-names>S.</given-names>
</string-name>
,
<string-name>
<surname>Whitmore</surname>
,
<given-names>T. E.</given-names>
</string-name>
, …
<string-name>
<surname>Roraback</surname>
,
<given-names>J</given-names>
</string-name>
. (
<year>2003</year>
).
<article-title>IL‐28, IL‐29 and their class II cytokine receptor IL‐28R</article-title>
.
<source xml:lang="en">Nature Immunology</source>
,
<volume>4</volume>
(
<issue>1</issue>
),
<fpage>63</fpage>
<pub-id pub-id-type="doi">10.1038/ni873</pub-id>
<pub-id pub-id-type="pmid">12469119</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0070">
<mixed-citation publication-type="journal" id="jnr24333-cit-0070">
<string-name>
<surname>Shichita</surname>
,
<given-names>T.</given-names>
</string-name>
,
<string-name>
<surname>Sugiyama</surname>
,
<given-names>Y.</given-names>
</string-name>
,
<string-name>
<surname>Ooboshi</surname>
,
<given-names>H.</given-names>
</string-name>
,
<string-name>
<surname>Sugimori</surname>
,
<given-names>H.</given-names>
</string-name>
,
<string-name>
<surname>Nakagawa</surname>
,
<given-names>R.</given-names>
</string-name>
,
<string-name>
<surname>Takada</surname>
,
<given-names>I.</given-names>
</string-name>
, …
<string-name>
<surname>Cua</surname>
,
<given-names>D. J.</given-names>
</string-name>
(
<year>2009</year>
).
<article-title>Pivotal role of cerebral interleukin‐17–producing γδT cells in the delayed phase of ischemic brain injury</article-title>
.
<source xml:lang="en">Nature Medicine</source>
,
<volume>15</volume>
(
<issue>8</issue>
),
<fpage>946</fpage>
<pub-id pub-id-type="doi">10.1038/nm.1999</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0071">
<mixed-citation publication-type="journal" id="jnr24333-cit-0071">
<string-name>
<surname>Stamatovic</surname>
,
<given-names>S. M.</given-names>
</string-name>
,
<string-name>
<surname>Keep</surname>
,
<given-names>R. F.</given-names>
</string-name>
,
<string-name>
<surname>Kunkel</surname>
,
<given-names>S. L.</given-names>
</string-name>
, &
<string-name>
<surname>Andjelkovic</surname>
,
<given-names>A. V.</given-names>
</string-name>
(
<year>2003</year>
).
<article-title>Potential role of MCP‐1 in endothelial cell tight junctionopening': Signaling via Rho and Rho kinase</article-title>
.
<source xml:lang="en">Journal of Cell Science</source>
,
<volume>116</volume>
(
<issue>22</issue>
),
<fpage>4615</fpage>
<lpage>4628</lpage>
.
<pub-id pub-id-type="doi">10.1242/jcs.00755</pub-id>
<pub-id pub-id-type="pmid">14576355</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0072">
<mixed-citation publication-type="journal" id="jnr24333-cit-0072">
<string-name>
<surname>Stevens</surname>
,
<given-names>S. L.</given-names>
</string-name>
,
<string-name>
<surname>Leung</surname>
,
<given-names>P. Y.</given-names>
</string-name>
,
<string-name>
<surname>Vartanian</surname>
,
<given-names>K. B.</given-names>
</string-name>
,
<string-name>
<surname>Gopalan</surname>
,
<given-names>B.</given-names>
</string-name>
,
<string-name>
<surname>Yang</surname>
,
<given-names>T.</given-names>
</string-name>
,
<string-name>
<surname>Simon</surname>
,
<given-names>R. P.</given-names>
</string-name>
, &
<string-name>
<surname>Stenzel‐Poore</surname>
,
<given-names>M. P</given-names>
</string-name>
. (
<year>2011</year>
).
<article-title>Multiple preconditioning paradigms converge on interferon regulatory factor‐dependent signaling to promote tolerance to ischemic brain injury</article-title>
.
<source xml:lang="en">Journal of Neuroscience</source>
,
<volume>31</volume>
(
<issue>23</issue>
),
<fpage>8456</fpage>
<lpage>8463</lpage>
.
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0821-11.2011</pub-id>
<pub-id pub-id-type="pmid">21653850</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0073">
<mixed-citation publication-type="journal" id="jnr24333-cit-0073">
<string-name>
<surname>Suárez</surname>
,
<given-names>Y.</given-names>
</string-name>
,
<string-name>
<surname>Wang</surname>
,
<given-names>C.</given-names>
</string-name>
,
<string-name>
<surname>Manes</surname>
,
<given-names>T. D.</given-names>
</string-name>
, &
<string-name>
<surname>Pober</surname>
,
<given-names>J. S.</given-names>
</string-name>
(
<year>2010</year>
).
<article-title>Cutting edge: TNF‐induced microRNAs regulate TNF‐induced expression of E‐selectin and intercellular adhesion molecule‐1 on human endothelial cells: Feedback control of inflammation</article-title>
.
<source xml:lang="en">The Journal of Immunology</source>
,
<volume>184</volume>
(
<issue>1</issue>
),
<fpage>21</fpage>
<lpage>25</lpage>
.
<pub-id pub-id-type="doi">10.4049/jimmunol.0902369</pub-id>
<pub-id pub-id-type="pmid">19949084</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0074">
<mixed-citation publication-type="journal" id="jnr24333-cit-0074">
<string-name>
<surname>Tiebosch</surname>
,
<given-names>I. A.</given-names>
</string-name>
,
<string-name>
<surname>Dijkhuizen</surname>
,
<given-names>R. M.</given-names>
</string-name>
,
<string-name>
<surname>Cobelens</surname>
,
<given-names>P. M.</given-names>
</string-name>
,
<string-name>
<surname>Bouts</surname>
,
<given-names>M. J.</given-names>
</string-name>
,
<string-name>
<surname>Zwartbol</surname>
,
<given-names>R.</given-names>
</string-name>
,
<string-name>
<surname>van der Meide</surname>
,
<given-names>P. H.</given-names>
</string-name>
, &
<string-name>
<surname>van den Bergh</surname>
,
<given-names>W. M</given-names>
</string-name>
. (
<year>2013</year>
).
<article-title>Effect of interferon‐β on neuroinflammation, brain injury and neurological outcome after experimental subarachnoid hemorrhage</article-title>
.
<source xml:lang="en">Neurocritical Care</source>
,
<volume>18</volume>
(
<issue>1</issue>
),
<fpage>96</fpage>
<lpage>105</lpage>
.
<pub-id pub-id-type="doi">10.1007/s12028-012-9692-2</pub-id>
<pub-id pub-id-type="pmid">22434548</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0075">
<mixed-citation publication-type="journal" id="jnr24333-cit-0075">
<string-name>
<surname>Veldhuis</surname>
,
<given-names>W. B.</given-names>
</string-name>
,
<string-name>
<surname>Derksen</surname>
,
<given-names>J. W.</given-names>
</string-name>
,
<string-name>
<surname>Floris</surname>
,
<given-names>S.</given-names>
</string-name>
,
<string-name>
<surname>van der Meide</surname>
,
<given-names>P. H.</given-names>
</string-name>
,
<string-name>
<surname>de Vries</surname>
,
<given-names>H. E.</given-names>
</string-name>
,
<string-name>
<surname>Schepers</surname>
,
<given-names>J.</given-names>
</string-name>
, …
<string-name>
<surname>Nicolay</surname>
,
<given-names>K.</given-names>
</string-name>
(
<year>2003</year>
).
<article-title>Interferon‐beta blocks infiltration of inflammatory cells and reduces infarct volume after ischemic stroke in the rat</article-title>
.
<source xml:lang="en">Journal of Cerebral Blood Flow & Metabolism</source>
,
<volume>23</volume>
(
<issue>9</issue>
),
<fpage>1029</fpage>
<lpage>1039</lpage>
.
<pub-id pub-id-type="doi">10.1097/01.WCB.0000080703.47016.B6</pub-id>
<pub-id pub-id-type="pmid">12973019</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0076">
<mixed-citation publication-type="journal" id="jnr24333-cit-0076">
<string-name>
<surname>Wack</surname>
,
<given-names>A.</given-names>
</string-name>
,
<string-name>
<surname>Terczyńska‐Dyla</surname>
,
<given-names>E.</given-names>
</string-name>
, &
<string-name>
<surname>Hartmann</surname>
,
<given-names>R.</given-names>
</string-name>
(
<year>2015</year>
).
<article-title>Guarding the frontiers: The biology of type III interferons</article-title>
.
<source xml:lang="en">Nature Immunology</source>
,
<volume>16</volume>
(
<issue>8</issue>
),
<fpage>802</fpage>
<pub-id pub-id-type="doi">10.1038/ni.3212</pub-id>
<pub-id pub-id-type="pmid">26194286</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0077">
<mixed-citation publication-type="journal" id="jnr24333-cit-0077">
<string-name>
<surname>Wang</surname>
,
<given-names>S.‐L.</given-names>
</string-name>
,
<string-name>
<surname>Duan</surname>
,
<given-names>L.</given-names>
</string-name>
,
<string-name>
<surname>Xia</surname>
,
<given-names>B.</given-names>
</string-name>
,
<string-name>
<surname>Liu</surname>
,
<given-names>Z.</given-names>
</string-name>
,
<string-name>
<surname>Wang</surname>
,
<given-names>Y.</given-names>
</string-name>
, &
<string-name>
<surname>Wang</surname>
,
<given-names>G.‐M.</given-names>
</string-name>
(
<year>2017</year>
).
<article-title>Dexmedetomidine preconditioning plays a neuroprotective role and suppresses TLR4/NF‐κB pathways model of cerebral ischemia reperfusion</article-title>
.
<source xml:lang="en">Biomedicine & Pharmacotherapy</source>
,
<volume>93</volume>
,
<fpage>1337</fpage>
<lpage>1342</lpage>
.
<pub-id pub-id-type="doi">10.1016/j.biopha.2017.06.051</pub-id>
<pub-id pub-id-type="pmid">28753906</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0078">
<mixed-citation publication-type="journal" id="jnr24333-cit-0078">
<string-name>
<surname>Wang</surname>
,
<given-names>Q.</given-names>
</string-name>
,
<string-name>
<surname>Tang</surname>
,
<given-names>X. N.</given-names>
</string-name>
, &
<string-name>
<surname>Yenari</surname>
,
<given-names>M. A.</given-names>
</string-name>
(
<year>2007</year>
).
<article-title>The inflammatory response in stroke</article-title>
.
<source xml:lang="en">Journal of Neuroimmunology</source>
,
<volume>184</volume>
(
<issue>1</issue>
),
<fpage>53</fpage>
<lpage>68</lpage>
.
<pub-id pub-id-type="doi">10.1016/j.jneuroim.2006.11.014</pub-id>
<pub-id pub-id-type="pmid">17188755</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0079">
<mixed-citation publication-type="journal" id="jnr24333-cit-0079">
<string-name>
<surname>Weinstein</surname>
,
<given-names>J. R.</given-names>
</string-name>
,
<string-name>
<surname>Koerner</surname>
,
<given-names>I. P.</given-names>
</string-name>
, &
<string-name>
<surname>Möller</surname>
,
<given-names>T.</given-names>
</string-name>
(
<year>2010</year>
).
<article-title>Microglia in ischemic brain injury</article-title>
.
<source xml:lang="en">Future Neurology</source>
,
<volume>5</volume>
(
<issue>2</issue>
),
<fpage>227</fpage>
<lpage>246</lpage>
.
<pub-id pub-id-type="doi">10.2217/fnl.10.1</pub-id>
<pub-id pub-id-type="pmid">20401171</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0080">
<mixed-citation publication-type="journal" id="jnr24333-cit-0080">
<string-name>
<surname>Wolinski</surname>
,
<given-names>P</given-names>
</string-name>
., &
<string-name>
<surname>Glabinski</surname>
,
<given-names>A</given-names>
</string-name>
. (
<year>2013</year>
).
<article-title>Chemokines and neurodegeneration in the early stage of experimental ischemic stroke</article-title>
.
<source xml:lang="en">Mediators of Inflammation</source>
,
<volume>2013, </volume>
<fpage>1</fpage>
<lpage>9</lpage>
.
<pub-id pub-id-type="doi">10.1155/2013/727189</pub-id>
.</mixed-citation>
</ref>
<ref id="jnr24333-bib-0081">
<mixed-citation publication-type="journal" id="jnr24333-cit-0081">
<string-name>
<surname>Xia</surname>
,
<given-names>W.</given-names>
</string-name>
,
<string-name>
<surname>Han</surname>
,
<given-names>J.</given-names>
</string-name>
,
<string-name>
<surname>Huang</surname>
,
<given-names>G.</given-names>
</string-name>
, &
<string-name>
<surname>Ying</surname>
,
<given-names>W.</given-names>
</string-name>
(
<year>2010</year>
).
<article-title>Inflammation in ischaemic brain injury: Current advances and future perspectives</article-title>
.
<source xml:lang="en">Clinical and Experimental Pharmacology and Physiology</source>
,
<volume>37</volume>
(
<issue>2</issue>
),
<fpage>253</fpage>
<lpage>258</lpage>
.
<pub-id pub-id-type="doi">10.1111/j.1440-1681.2009.05279.x</pub-id>
<pub-id pub-id-type="pmid">19719754</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0082">
<mixed-citation publication-type="journal" id="jnr24333-cit-0082">
<string-name>
<surname>Zaremba</surname>
,
<given-names>J.</given-names>
</string-name>
,
<string-name>
<surname>Ilkowski</surname>
,
<given-names>J.</given-names>
</string-name>
, &
<string-name>
<surname>Losy</surname>
,
<given-names>J.</given-names>
</string-name>
(
<year>2006</year>
).
<article-title>Serial measurements of levels of the chemokines CCL2, CCL3 and CCL5 in serum of patients with acute ischaemic stroke</article-title>
.
<source xml:lang="en">Folia Neuropathologica</source>
,
<volume>44</volume>
(
<issue>4</issue>
),
<fpage>282</fpage>
<lpage>289</lpage>
.
<pub-id pub-id-type="pmid">17183455</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0083">
<mixed-citation publication-type="journal" id="jnr24333-cit-0083">
<string-name>
<surname>Zhang</surname>
,
<given-names>R.</given-names>
</string-name>
,
<string-name>
<surname>Chopp</surname>
,
<given-names>M.</given-names>
</string-name>
,
<string-name>
<surname>Zhang</surname>
,
<given-names>Z.</given-names>
</string-name>
,
<string-name>
<surname>Jiang</surname>
,
<given-names>N.</given-names>
</string-name>
, &
<string-name>
<surname>Powers</surname>
,
<given-names>C.</given-names>
</string-name>
(
<year>1998</year>
).
<article-title>The expression of P‐and E‐selectins in three models of middle cerebral artery occlusion</article-title>
.
<source xml:lang="en">Brain Research</source>
,
<volume>785</volume>
(
<issue>2</issue>
),
<fpage>207</fpage>
<lpage>214</lpage>
.
<pub-id pub-id-type="doi">10.1016/S0006-8993(97)01343-7</pub-id>
<pub-id pub-id-type="pmid">9518615</pub-id>
</mixed-citation>
</ref>
<ref id="jnr24333-bib-0084">
<mixed-citation publication-type="journal" id="jnr24333-cit-0084">
<string-name>
<surname>Zipp</surname>
,
<given-names>F.</given-names>
</string-name>
, &
<string-name>
<surname>Aktas</surname>
,
<given-names>O.</given-names>
</string-name>
(
<year>2006</year>
).
<article-title>The brain as a target of inflammation: Common pathways link inflammatory and neurodegenerative diseases</article-title>
.
<source xml:lang="en">Trends in Neurosciences</source>
,
<volume>29</volume>
(
<issue>9</issue>
),
<fpage>518</fpage>
<lpage>527</lpage>
.
<pub-id pub-id-type="doi">10.1016/j.tins.2006.07.006</pub-id>
<pub-id pub-id-type="pmid">16879881</pub-id>
</mixed-citation>
</ref>
</ref-list>
</back>
</pmc>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000952 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000952 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    StressCovidV1
   |flux=    Pmc
   |étape=   Corpus
   |type=    RBID
   |clé=     PMC:7167007
   |texte=   Therapeutic spectrum of interferon‐β in ischemic stroke
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i   -Sk "pubmed:30320448" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a StressCovidV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed May 6 16:44:09 2020. Site generation: Sun Mar 28 08:26:57 2021